Document:

Amended Investors Rights Agreement

  
 Exhibit 4.8 

 
 ACCENTIA BIOPHARMACEUTICALS, INC. 
  
 AMENDED AND RESTATED 
  
 INVESTORS’ RIGHTS AGREEMENT 
  
 This Amended and Restated Investors’ Rights Agreement (this
“Agreement”) is made as of January 7, 2005 by and among ACCENTIA BIOPHARMACEUTICALS, INC., a Florida corporation, having its principal place of business located at 5310 Cypress Center Drive, Suite 101, Tampa, FL 33609
(the “Company”), and Pharmaceutical Product Development, Inc., a North Carolina corporation, having its principal place of business located at 3151 South 17th Street, Wilmington, NC 28412 (“PPD”), and supersedes and replaces in its entirety that certain Investors’ Rights Agreement dated
January 9, 2004 by and between the Company and PPD (the “Original Agreement”). 
  
 RECITALS 
  
 Whereas, PPD is a party to the Series E Convertible Preferred Stock Purchase Agreement dated January 9, 2004 by and between the Company and PPD (the “Series E Stock Purchase Agreement”), which provided that,
as a condition to the closing of the sale of 5,000,000 shares of the Company’s Series E Convertible Preferred Stock (the “Series E Stock”) to PPD, the Original Agreement must be executed and delivered by the Company;

  
 Whereas, in connection with the closing of the
transactions contemplated by the Series E Stock Purchase Agreement, the Company issued to PPD a Class A Warrant (the “Class A Warrant”) to purchase up to 5,000,000 shares of Series E Stock, the term of which warrant is set to expire
on January 9, 2005; 
  
 WHEREAS, PPD commits to exercise
the Class A warrant for the purchase of 5,000,000 shares of Series E Stock upon signing hereof and expresses its current intent, without obligation and based on current facts and circumstances, to exercise the Class B Warrant at the closing of the
Planned IPO for the purchase of an additional 5,000,000 shares of Series E Stock; 
  
 Whereas, as soon as practicable the Company is planning to file a registration statement with the Securities and Exchange Commission to register the underwritten offer and sale of its Common Stock to the public
under the Act (the “Planned IPO”) in a manner intended to qualify the Planned IPO as a Qualifying IPO; 
  
 Whereas, the parties desire to set forth herein the terms under which the Company agrees to include and sell in the Planned IPO all of the shares
of Common Stock issuable to PPD up to a maximum gross proceeds on behalf of PPD of Twelve Million Dollars ($12,000,000) which may be expanded in the discretion of the Underwriter and the Company (the “PPD Original Investment
Shares”) upon the 

  

 
automatic conversion of the 5,000,000 shares of Series E Stock currently held by PPD which would convert into such Common Stock upon a Qualifying IPO.

  
 Now, Therefore, in consideration of the mutual promises
and covenants set forth herein, the parties hereto further agree as follows: 
  
 AGREEMENT 
  
 1.
Registration Rights. The Company covenants and agrees as follows: 
  
 1.1 Definitions. For purposes of this Section 1: 
  
 (a) The term “register,” “registered,” and “registration” refer to a registration
effected by preparing and filing a registration statement or similar document in compliance with the Securities Act of 1933, as amended (the “Act”), and the declaration or ordering of effectiveness of such registration
statement or document; 
  
 (b) The term
“Registrable Securities” means the (i) Common Stock issuable or issued upon conversion of the Series E Stock issued or issuable in connection with the Series E Stock Purchase Agreement (including the PPD Original Investment
Shares), whether such Series E Stock is issued at the Closing or subsequent thereto upon the exercise of any warrants issued to PPD pursuant to the Series E Stock Purchase Agreement ; and (ii) any Common Stock of the Company issued as (or issuable
upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, any Series E Stock; 
  
 (c) The number of shares of “Registrable
Securities then outstanding” shall be determined by the number of shares of Common Stock outstanding which are, and the number of shares of Common Stock issuable pursuant to then exercisable or convertible securities which are,
Registrable Securities; 
  
 (d) The term
“Holder” means any person owning or having the right to acquire Registrable Securities or any assignee thereof in accordance with Section 1.13 hereof, including PPD; and 
  
 (e) The term “Form S-3” means such
form under the Act as in effect on the date hereof or any registration form under the Act subsequently adopted by the Securities and Exchange Commission (the “SEC”) which permits inclusion or incorporation of substantial
information by reference to other documents filed by the Company with the SEC. 
  
 The term “Qualifying IPO” means the closing of a firm commitment underwritten public offering pursuant to an effective registration statement under the Act, as amended, covering the offer and
sale of Common Stock for the account of the Company to the public (an “Initial Public Offering”) in which the public offering price exceeds (prior to underwriter’s discounts or commissions 

  

 
and offering expenses) a price per share (adjusted for any subsequent stock splits, stock dividends, reclassifications or recapitalizations) that implies a
minimum aggregate enterprise value for the Company, on a fully diluted share basis, of not less than $200,000,000 and the aggregate gross proceeds raised by the Company (after all underwriting discounts) shall equal or exceed $30,000,000.

  
 1.2 Required Registration. 

 
 (a) The Company agrees that in connection with its
Planned IPO it shall undertake best efforts to file a registration statement with the SEC within the next 30 days covering the firm commitment underwritten offer and sale in the Planned IPO of all of the PPD Original Investment Shares. The Company
shall use its best efforts to have the registration statement declared effective by the SEC as soon as practicable, and shall diligently proceed in a good faith effort to respond to SEC comments and complete the Planned IPO within 150 days from the
date hereof. The Company may in its discretion delay or postpone the IPO if the Board in good faith determines that it would not be advisable and in the best interest of the Company and its shareholders. The Company agrees that it will not include
any shares in the IPO held by stockholders other than PPD without PPD’s prior written consent. The Company shall include all of the PPD Original Investment Shares for offer and sale in the Planned IPO (or any other Initial Public Offering of
Company shares, whether contemplated now or in the future), and this obligation is and shall be absolute and unconditional. Without the prior written consent of PPD, the Company shall not under any circumstances complete the Planned IPO (or any
other Initial Public Offering of it shares) without including therein all of the PPD Original Investment Shares as defined herein for sale to and through the underwriters for such offering. 
  
 (b) PPD shall (together with the Company as provided in
Section 1.5(e)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected by the Company. If the underwriter advises the Company or PPD in writing that marketing factors require a limitation of the number
of shares to be underwritten, there shall be no reduction to the number of PPD Original Investment Shares underwritten and included in the Planned IPO without the prior written consent of PPD, and any such reduction shall only be made to the Company
shares to be included in the Planned IPO. The Company shall notify PPD in advance of completion of the Planned IPO if the Planned IPO is not going to qualify as a Qualifying IPO and PPD shall have the right and the opportunity to withdraw any or all
of its shares from the Planned IPO without penalty. 
  
 (c) In the event the Company completes (or proposes to complete) the Planned IPO or any other Initial Public Offering and fails (or it becomes apparent that it intends to fail) for any reason to register, offer and sell all of the PPD
Original Investment Shares (which are not voluntarily withdrawn by PPD) in such underwritten registration (and remit all the net proceeds therefrom to PPD), then the Company shall be in immediate breach of its obligations to PPD and PPD shall have
the right to pursue any and all such damages or other remedies 

  

 
available to it at law or in equity. PPD shall have the full unrestricted right, without limitation, to pursue in a court of competent jurisdiction, and if
awarded by the court recover from the Company, such damages or other relief as may be necessary to compensate PPD for any and all actual or anticipatory damages or losses it may incur as a result of the Company’s failure to perform under this
Agreement, including under this Section 1.2 specifically. In determining damages, PPD shall be required to take reasonable actions to mitigate its loss and damages. 
  
 The parties acknowledge and agree that but for the Company’s agreement to include the PPD Original
Investment Shares for sale in the Planned IPO, PPD would not have exercised the Class A Warrant. 
  
 1.3 Request for Registration. 
  
 (a) If the Company shall receive at any time after the end of the term of the lock up pursuant to Section 4.12 (other than a registration
statement relating either to the sale of securities to employees of the Company pursuant to a stock option, stock purchase or similar plan or a SEC Rule 145 transaction) (the “Initial Registration”), a written request from
the Holders of at least twenty percent (20%) of the Registrable Securities (the “Initiating Holders”) that the Company file a registration statement under the Act covering the registration of such Holders’ Registrable
Securities with an aggregate offering price expected to exceed $2,000,000, then the Company shall, within ten (10) days of the receipt thereof, give written notice of such request to all Holders and shall, subject to the limitations of Section
1.3(b), use its best efforts to effect as soon as practicable the registration under the Act of all Registrable Securities which the Holders request to be registered within twenty (20) days of the mailing of such written notice by the Company;
provided, however, that the Company shall not be obligated to take any action to effect any such registration, qualification or compliance pursuant to this Section 1.3(a): 
  
 (i) During the period starting with the date ninety (90) days prior to the Company’s estimated
date of filing of, and ending on the date one hundred eighty (180) days immediately following the effective date of, any registration statement pertaining to securities of the Company (other than a registration of securities in a Rule 145
transaction or with respect to an employee benefit plan), provided that the Company is actively employing in good faith all reasonable efforts to cause such registration statement to become effective; 
  
 (ii) After the Company has effected two (2) such
registrations pursuant to this Section 1.3(a), and such registrations have been declared or ordered effective; 
  
 (iii) If the Company shall furnish to such Holders a certificate signed by the Chief Executive Officer or President of the Company
stating that in the good faith judgment of the Board of Directors it would be seriously detrimental to the Company or its stockholders for a registration statement to be filed at such time, then the Company’s obligation to use its best efforts
to register, qualify or comply under this 

  

 
Section 1.3(a) shall be deferred for a period not to exceed 60 days (which may be extended by the Company for an additional 60 days if in the good faith
judgment of the Board of Directors the serious detriment was continuing) from the date of receipt of written request from the Holders; provided, however, that the Company may not utilize this right more than once in any twelve-month
period; 
  
 (iv) During any lock-up period
agreed to by Holder. 
  
 (b) If the Initiating
Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 1.3, and the Company shall include such
information in the written notice referred to in Section 1.3(a). In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such
underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided herein. All Holders
proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section 1.5(e)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such
underwriting by a majority in interest of the Initiating Holders. Notwithstanding any other provision of this Section 1.3, if the underwriter advises the Initiating Holders in writing that marketing factors require a limitation of the number of
shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities which would otherwise be underwritten pursuant hereto, and the number of shares of Registrable Securities that may be included in the
underwriting shall be allocated among all Holders thereof, including the Initiating Holders, in proportion (as nearly as practicable) to the amount of Registrable Securities of the Company owned by each Holder participating in such underwriting.

  
 1.4 Company Registration. If
(but without any obligation to do so) the Company proposes to register (including for this purpose a registration effected by the Company for stockholders other than the Holders) any of its stock or other securities under the Act in connection with
the public offering of such securities solely for cash (other than a registration relating solely to the sale of securities to participants in a Company stock plan, or a registration on any form which does not include substantially the same
information as would be required to be included in a registration statement covering the sale of the Registrable Securities), the Company shall, at such time, promptly give each Holder written notice of such registration. Upon the written request of
each Holder given within twenty (20) days after mailing of written notice by the Company, the Company shall, subject to the provisions of Section 1.9, cause to be registered under the Act all of the Registrable Securities that each such Holder has
requested to be registered. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 1.4 prior to the effectiveness of such registration whether or not any Holder has elected to include securities
in such registration. The registration expenses of such withdrawn registration shall be borne by the Company in accordance with Section 1.8 hereof. 
  

 1.5 Obligations of the Company. Whenever required under this Section 1 to
effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
  
 (a) Prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its best efforts to cause
such registration statement to become effective, and keep such registration statement effective for the earlier of ninety (90) days from the effective date of the Registration Statement or until the distribution described in the Registration
Statement has been completed. 
  
 (b) Prepare and
file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Act with respect to the disposition of
all securities covered by such registration statement. 
  
 (c) Furnish to the Holders such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Act, and such other documents as they may reasonably request in order to facilitate the
disposition of Registrable Securities owned by them. 
  
 (d) Use its best efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided,
however, that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions. 
  
 (e) In the event of any underwritten public offering, enter
into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under
such an agreement. 
  
 (f) Notify each Holder
covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in
effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. 
  
 (g) Furnish, at the request of PPD (in the case of a
registration effected pursuant to Section 1.2) or any Holder requesting registration of Registrable Securities pursuant to this Section 1, on the date that such 

  

 
Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1, if such securities are being
sold through underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective, an opinion, dated such date, of the counsel representing the
Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to PPD and the Holders requesting registration of Registrable
Securities. 
  
 1.6 Furnish
Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company,
promptly upon request, such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as shall be required to effect the registration of such Holder’s Registrable Securities.

  
 1.7 Expenses of Registrations.
The Company shall bear and pay all expenses incurred in connection with any registration, filing or qualification of Registrable Securities (including the PPD Original Investment Shares) with respect to the registrations pursuant to Sections 1.2,
1.3, 1.4 and 1.12 for each Holder (which right may be assigned as provided in Section 1.13), including (without limitation) all registration, filing, and qualification fees, printers and accounting fees relating or apportionable thereto, , but
excluding stock transfer taxes, and any underwriting discounts and commissions and any legal fees incurred by Holder relating to Registrable Securities. 
  
 1.8 Underwriting Requirements. In connection with any offering involving an underwriting of shares being issued by the
Company, the Company shall not be required under Section 1.2, 1.3 or 1.4 to include any of the Holders’ securities in such underwriting unless they accept the terms of the underwriting as agreed upon between the Company and the underwriters
selected by it (or by other persons entitled to select the underwriters), and then, but only in the case of a registration undertaken pursuant to Section 1.4 and not Section 1.2 and 1.3, only in such quantity as will not, in the opinion of the
underwriters, jeopardize the success of the offering by the Company, but in no event will the amount of Registrable Securities of the selling Holders included in the offering be reduced below twenty percent (20%) of the total amount of securities
included in such offering,. Except in the case of a registration undertaken pursuant to Section 1.2 (in which case PPD’s rights to have the PPD Original Investment Shares included are absolute, unconditional and not subject to cutback without
the prior written consent of PPD) , if the underwriter determines in good faith that marketing factors require a limitation in the number of shares to be underwritten, the number of shares that may be included in the underwriting shall be allocated
(i) first, to the Company; (ii) second to the Holders on a pro rata basis based on the number of Registrable Securities held by the Holders; and (iii) third to any other stockholder of the Company (other than a Holder) on a pro rata basis;
provided, however, that in no event shall any Holder be restricted from including such Holder’s Registrable Securities in an offering pursuant to this Section 1.8 unless and until all other holders of securities of the Company
have been entirely restricted. For purposes of 

  

 
apportionment, any selling stockholder which is a Holder of Registrable Securities and which is a partnership or corporation, the partners, retired partners
and stockholders of such Holder, or the estates and family members of any such partners and retired partners and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “selling stockholder,” and any pro
rata reduction with respect to such “selling stockholder” shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such “selling stockholder,” as defined in
this sentence. 
  
 1.9 Delay of
Registration under Section 1.3 or 1.4 No Holder shall have the right to obtain or seek an injunction restraining or otherwise delaying any registration under Section 1.3 or 1.4 as a result of any controversy that might arise with respect to the
interpretation or implementation of Section 1.3 or 1.4 hereof. 
  
 1.10 Indemnification. In the event any Registrable Securities (including the PPD Original Investment Shares) are included in a registration statement under this Section 1: 
  
 (a) To the extent permitted by law, the Company will
indemnify and hold harmless each Holder, any underwriter (as defined in the Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Act or the Securities Exchange Act of 1934, amended (the
“1934 Act”), against any losses, claims, damages, or liabilities (joint or several) to which such Holder, underwriter or controlling person may become subject under the Act, the 1934 Act or other federal or state law, insofar
as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations of the Company (collectively a “Violation”): (i) any
untrue statement or alleged untrue statement of the Company of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the
omission or alleged omission by the Company to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Act, the 1934
Act, any state securities law or any rule or regulation promulgated under the Act, the 1934 Act or any state securities law; and the Company will pay to each such Holder, underwriter or controlling person, as incurred, any legal or other expenses
reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this Section 1.10(a) shall not apply to amounts
paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case for any
such loss, claim, damage, liability, or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such registration
by any such Holder, underwriter or controlling person. 
  

 (b) To the extent permitted by law, each selling Holder will severally, not jointly,
indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of the Act, any underwriter, any other Holder selling
securities in such registration statement and any controlling person of any such underwriter or other Holder, against any losses, claims, damages, or liabilities (joint or several) to which any of the foregoing persons may become subject, under the
Act, the 1934 Act or other federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such
Violation occurs in reliance upon and in conformity with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will pay, as incurred, any legal or other expenses reasonably incurred
by any person intended to be indemnified pursuant to this Section 1.10(b), in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in
this Section 1.10(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided,
that, in no event shall any indemnity under this Section 1.10(b) exceed the net proceeds from the offering received by such Holder, except in the case of willful fraud by such holder. 
  
 (c) Promptly after receipt by an indemnified party under this Section 1.10 of notice of the commencement of
any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.10, deliver to the indemnifying party a written notice of the commencement
thereof, and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by
the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written
notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section
1.10, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 1.10. 
  
 (d) If the indemnification provided for in this Section 1.10
is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to therein, then the indemnifying party, in lieu of indemnifying such 

  

 
indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage or
expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability,
claim, damage or expense as well as any other relevant equitable considerations; provided, that, in no event shall any indemnity under this Section 1.10(d) exceed the net proceeds from the offering received by such Holder, except in the case of
willful fraud by such Holder. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to
state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

  
 (e) Notwithstanding the foregoing, to the
extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting
agreement shall control. 
  
 (f) The obligations
of the Company and Holders under this Section 1.10 shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 1, and otherwise. 
  
 1.11 Reports Under Securities Exchange Act of 1934. With a view to making available to the
Holders the benefits of Rule 144 promulgated under the Act (“Rule144”) and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or
pursuant to a registration on Form S-3, the Company agrees to: 
  
 (a) make and keep public information available, as those terms are understood and defined in Rule 144, at all times after the effective date of the first registration statement filed by the Company for the offering of
its securities to the general public; 
  
 (b)
take such action, including the voluntary registration of its Common Stock under Section 12 of the 1934 Act, as is necessary to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities, such action to be taken as soon as
practicable after the end of the fiscal year in which the first registration statement filed by the Company for the offering of its securities to the general public is declared effective; 
  
 (c) file with the SEC in a timely manner all reports and
other documents required of the Company under the Act and the 1934 Act; and 
  
 (d) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the 

  

 
Company that it has complied with the reporting requirements of Rule 144 (at any time after ninety (90) days after the effective date of the first
registration statement filed by the Company), the Act and the 1934 Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time
after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of
any rule or regulation of the SEC which permits the selling of any such securities without registration or pursuant to such form. 
  
 1.12 Form S-3 Registration. In case the Company shall receive from any Holder or Holders who hold in excess of thirty
percent (30%) of the Registrable Securities, a written request or requests that the Company effect a registration on Form S-3 and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such
Holder or Holders, the Company will: 
  
 (a)
promptly give written notice of the proposed registration, and any related qualification or compliance, to all other Holders; and 
  
 (b) as soon as practicable, effect such registration and all such qualifications and compliances as may be so requested and as would
permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder
or Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company; provided, however, that the Company shall not be obligated to effect any
such registration, qualification or compliance, pursuant to this Section 1.12: (i) if Form S-3 is not available for such offering by the Holders; (ii) if the Holders, together with the holders of any other securities of the Company entitled to
inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public (net of any underwriters’ discounts or commissions) of less than $500,000; (iii) if the Company shall
furnish to the Holders a certificate signed by the Chief Executive Officer or President of the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its
stockholders for such Form S-3 Registration to be effected at such time, in which event the Company shall have the right to defer the filing of the Form S-3 registration statement for a period of not more than 60 days (which may be extended by the
Company for an additional 60 days if in the good faith judgment of the Board of Directors the serious detriment was continuing) after receipt of the request of the Holder or Holders under this Section 1.12; provided, however, that the
Company shall not utilize this right more than once in any twelve (12) month period; or (iv) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in
effecting such registration, qualification or compliance. 
  

 (c) If the Holders initiating the registration request hereunder (the
“Participating Holders”) intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as part of their request made pursuant to this Section 1.12 and
the Company shall include such information in the written notice referred to in Section 1.12(a). In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Participating Holders and such Holder) to the
extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section 1.5(e)) enter into an underwriting agreement in customary form with the underwriter or
underwriters selected for such underwriting by a majority in interest of the Participating Holders. Notwithstanding any other provision of this Section 1.12, if the underwriter advises the Participating Holders in writing that marketing factors
require a limitation of the number of shares to be underwritten, then the Participating Holders shall so advise all Holders of Registrable Securities which would otherwise be underwritten pursuant hereto, and the number of shares of Registrable
Securities that may be included in the underwriting shall be allocated among all Holders thereof, including the Participating Holders, in proportion (as nearly as practicable) to the amount of Registrable Securities of the Company owned by each
Holder. 
  
 (d) Subject to the foregoing, the
Company shall file a registration statement covering the Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the request or requests of the Holders. Registrations effected pursuant to
this Section 1.12 shall not be counted as the required registration under Section 1.2 or the demand for registration or registrations effected pursuant to Sections 1.3 or 1.4, respectively. 
  
 1.13 Assignment of Registration Rights. The
rights to cause the Company to register shares in the Planned IPO pursuant hereto may not be assigned by a Holder. The rights to cause the Company to register Registrable Securities (other than in the Planned IPO) may be assigned by a Holder to any
of the following transferees or assignees of Registrable Securities: (i) any such transferee or assignee who holds, subsequent to such transfer, five percent (5%) of the total number of shares of Registrable Securities (as adjusted for stock splits,
bonuses, combinations, and the like); or (ii) a subsidiary, wholly-owned entity, parent, affiliate, member, stockholder, officer, general partner, limited partner or former or retired partner or member of a Holder; or (iii) a Holder’s family
member or trust for the benefit of an individual Holder or any family member; provided, however, that (a) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such
transferee or assignee and the securities with respect to which such registration rights are being assigned and (b) such assignment shall be effective only if immediately following such transfer the transferee is bound by the terms and conditions of
this Agreement and such transfer of any Registrable Securities is lawful under all applicable securities laws. 
  

 1.14 Termination of Registration Rights. No stockholder shall be entitled to
exercise any right provided for in this Section 1 (except rights pursuant to Sections 1.2 or 1.11) after the earlier of (i) three (3) years following the consummation of the sale of securities pursuant to an Initial Public Offering, or (ii) as to a
given Holder, when such Holder can sell all of such Holder’s Registrable Securities in a consecutive ninety (90) day period pursuant to Rule 144. 
  
 1.15 Limitations on Subsequent Registration Rights. Except with respect to substantially identical registration rights that may be
granted to other holders of Series E Stock and Series F Convertible Preferred Stock (“Series F Stock”), if created, with respect to such Series E Stock or Series F Stock (and the Common Stock obtained upon conversion) held by them,
the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities, enter into any agreement (other than this Agreement) with any holder or prospective holder of any securities of the Company which
would allow such holder or prospective holder (i) to include securities of the Company in any Registration Statement upon terms which are the same or more favorable to such holder or prospective holder than the terms on which holders of Registrable
Securities may include shares in such registration or (ii) to make a demand registration which could result in such registration statement being declared effective prior to the dates set forth in Section 1.2. Notwithstanding the foregoing, in no
event shall the Company grant any rights to any stockholder (other than to PPD) granting them any right to include shares for registration, offer and sale in the Planned IPO 
  
 2. Information Rights. 
  
 2.1 Inspection. The Company shall permit each Holder holding, together with its affiliates (which may include, without
limitation, any person or entity to which rights can be transferred pursuant to Section 3.4, below), an aggregate of at least 1,000,000 shares of the Series E Stock (each, a “Major Holder” and collectively, the
“Major Holders”), at such Major Holder’s expense to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its
officers, all at such reasonable times as may be requested by the Major Holder; provided, however, that the Company shall not be obligated pursuant to this Section 2.1 to provide access to any information which it reasonably considers
to be a trade secret or similar confidential information unless such Major Holder agrees in writing to hold such information in confidence. 
  
 2.2 Delivery of Financial Statements. 
  
 (a) The Company shall deliver to each Holder of Series E Stock: 
  
 (1) as soon as practicable, but in any event within
one hundred twenty (120) days after the end of each fiscal year of the Company commencing with the fiscal year ended December 31, 2003, a balance sheet dated as of the last day of such fiscal year, and statements of operations, cash flow and 

  

 
stockholders’ equity for such fiscal year. Such year-end financial reports to be in reasonable detail, prepared in accordance with generally accepted
accounting principles (“GAAP”), and audited and certified by independent public accountants of nationally recognized standing selected by the Company; 
  
 (2) within forty five (45) days of the end of each fiscal quarter of the Company commencing with the
fiscal quarter ended December 31, 2003, an unaudited statement of operations and balance sheet for and as of the end of such quarter, in reasonable detail and prepared in accordance with GAAP, subject to year end audit adjustments and the absence of
footnotes; and 
  
 (b) The Company shall deliver
to each Major Holder: 
  
 (1) as soon as
practicable, but in any event within thirty (30) days prior to the end of the Company’s fiscal year, an annual budget and operating plan for the Company for the following fiscal year; 
  
 (2) as soon as practicable after the end of each
month, and in any event within thirty (30) days thereafter, an unaudited statement of operations and balance sheet for such month, in reasonable detail and prepared in accordance with GAAP, subject to year end audit adjustments and the absence of
footnotes. 
  
 2.3 Termination of
Information Rights. The covenants set forth in this Section 2 shall terminate as to all Holders and Major Holders and be of no further force and effect (i) upon the consummation of a Qualifying IPO or (ii) when the Company first becomes subject
to the periodic reporting requirements of Section 12(g) or 15(d) of the Securities Exchange Act of 1934, whichever event shall first occur. 
  
 3. Investors’ Right of First Refusal. 
  
 3.1 Right of First Refusal. The Company hereby grants to each Holder, on the terms set forth in this Section 3, the right of
first refusal to purchase all or any part of such Holder’s pro rata share of the New Securities (as defined in Section 3.2) which the Company may, from time to time, propose to sell and issue (the “Right of First
Refusal”). The Holders may purchase said New Securities on the same terms and at the same price at which the Company proposes to sell the New Securities. For the purposes of this right of first refusal, a Holder’s pro rata share of
the New Securities is a fraction, the numerator of which is the total number of shares of Series E Convertible Preferred Stock held by such Holder and the denominator of which is the total number of shares of the Company’s capital stock (Common
Stock and Preferred Stock) outstanding immediately prior to the issuance of the New Securities; provided, however, if it is impossible or impractical, as determined in the sole discretion of Holder’s of a majority of the Series E Stock, to
determine the applicable pro rata percentage in accordance with the preceding sentences of this Section 3.1, then such majority may elect for the applicable pro rata percentage to be set at 15%. 
  

 3.2 New Securities. “New Securities” shall mean any
capital stock of the Company, whether now authorized or not, and any rights, options or warrants to purchase said capital stock, and securities of any type whatsoever that are, or may become, convertible into said capital stock; provided,
however, that New Securities shall not include (i) the Series E Stock, (ii) shares of Common Stock issuable upon conversion of Preferred Stock, (iii) securities offered pursuant to a registration statement filed under the Act, (iv) securities
issued pursuant to the acquisition of another corporation by the Company by merger, purchase of substantially all of the assets or other reorganization, or in any transaction in which the Company’s stockholders immediately prior to such
transaction own immediately after such transaction not less than 51% of the voting power of the surviving corporation or its parent, (v) up to 10,000,000 shares of capital stock and/or stock options issued to officers, employees, consultants or
advisors pursuant to the Company’s stock option plans; (vi) securities issued in connection with leases or bank financing arrangements or corporate partnering, licensing or similar transactions, provided that such transactions and the issuance
of shares therein has been approved by the Board of Directors of the Company, (vii) any warrants, options or rights (and any shares of Common Stock or Preferred Stock issued or issuable upon the exercise of such warrants, options or rights) to
purchase shares of Common Stock or Preferred Stock that are outstanding as of the date of this Agreement, and (viii) securities issued in connection with any stock split, stock dividend or distribution, or recapitalization by the Company approved by
the Company’s Board of Directors. 
  
 3.3
Notice of Proposed Issuance. In the event the Company proposes to undertake an issuance of New Securities, it shall give to the Holders written notice (the “Notice”) of its intention, describing the type of New
Securities, the price, the terms upon which the Company proposes to issue the same, the date of the proposed issuance and a statement as to the number of days from receipt of such Notice within which the Holders must respond to such Notice. The
Holders shall have twenty (20) days from the date of receipt of the Notice to purchase any or all of the New Securities for the price and upon the terms specified in the Notice by giving written notice to the Company and stating therein the quantity
of New Securities to be purchased and forwarding payment for such New Securities to the Company if immediate payment is required by such terms, or in any event no later than the date of the proposed issuance as set forth in the Notice. If not all of
the Holders elect to purchase their pro rata share of the New Securities, then the Company shall promptly notify in writing the Holders who do so elect to purchase all of their pro rata portion of the New Securities and shall offer such subscribing
Holders the right to acquire their pro rata portion of any unsubscribed New Securities. Each subscribing Holder shall have five (5) days after receipt of such notice to notify the Company in writing of its election to purchase all of its pro rata
portion of the unsubscribed New Securities. If the Holders fail to exercise in full their first refusal rights, the Company may sell the New Securities for which the Holders first refusal rights were not exercised, at a price and upon terms and
conditions no more favorable then specified in the Notice. 
  
 3.4 Transfer of Rights. The right of first refusal granted under this Section 3 may not be assigned or transferred, except that such right is assignable or transferable by each Holder to any transferee
or assignee (i) who is a partner or member (or 

  

 
retired partner or member) of a Holder or the estate of such partner or member (or retired partner or member) or (ii) that is a wholly owned subsidiary or
parent of, or to any corporation or entity that is, within the meaning of the Act, controlling, controlled by or under common control with, any such Holder; provided, however, that the provisions of this Section 3 shall be binding upon
any such assignee or transferee. 
  
 3.5
Termination of Rights. The right of first refusal granted under this Section 3 shall expire upon the first to occur of (i) consummation of a Qualifying IPO, (ii) the sale, assignment or other transfer of the Registrable Securities or the
Series E Stock, or (iii) the conversion of the Series E Stock into Common Stock. 
  
 4. Miscellaneous Provisions. 
  
 4.1 Waivers and Amendments. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively
or prospectively), only with the written consent of the Company and the Holders of at least a majority of the Registrable Securities. Any amendment or waiver effected in accordance with this Section 4.1 shall be binding upon each person or entity
which are granted certain rights under this Agreement and the Company. 
  
 4.2 Notices. All notices and other communications required or permitted hereunder shall be in writing and, except as otherwise noted herein, shall be deemed effectively given (i) upon personal delivery
or delivery by nationally recognized courier, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day, or (iii) five (5) days after having been deposited
with the United States Post Office, (by registered or certified mail, return receipt requested, postage prepaid) addressed (a) if to the Company, at the address set forth on the first page of this Agreement (or at such other address as the Company
shall have furnished to the Holders in writing) attention of Chief Executive Officer and (b) if to a Holder, at the latest address of such person shown on the Company’s records; provided, however, that registered or certified mail
shall not be used to effectuate delivery of any such notice under this Agreement if the party to be notified is located outside of the United States. 
  
 4.3 Descriptive Headings. The descriptive headings herein have been inserted for convenience only and shall not be deemed to
limit or otherwise affect the construction of any provisions hereof. 
  
 4.4 Governing Law. This Agreement shall be governed by and interpreted under the laws of the State of Florida as applied to agreements among Florida residents, made and to be performed entirely within
the State of Florida. 
  
 4.5
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original and all of which shall constitute the same instrument, but only one of which need be produced.

  

 4.6 Expenses. If any action at law or in equity is necessary to enforce or
interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 
  
 4.7 Successors and Assigns. Except as
otherwise expressly provided in this Agreement, this Agreement shall benefit and bind the successors, assigns, heirs, executors and administrators of the parties to this Agreement. 
  
 4.8 Entire Agreement. This Agreement constitutes the full and entire understanding and
agreement between the parties with regard to the subject matter of this Agreement. This Agreement amends, supersedes and replaces in its entirety all other agreements between or among any of the parties with respect to the subject matter hereof
(including the Original Agreement). 
  
 4.9
Separability; Severability. Unless expressly provided in this Agreement, the rights and obligations of each Holder under this Agreement are several and not jointly held with any other Holders. Any invalidity, illegality or limitation on
the enforceability of this Agreement with respect to any Holder shall not affect the validity, legality or enforceability of this Agreement with respect to the other Holders. If any provision of this Agreement is judicially determined to be invalid,
illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not be affected or impaired. 
  
 4.10 Stock Splits. All references to numbers of shares in this Agreement shall be appropriately adjusted to reflect any
stock dividend, split, combination or other recapitalization of shares by the Company occurring after the date of this Agreement. 
  
 4.11 Aggregation of Stock. All shares of the Series E Stock held or acquired by affiliated entities or persons shall be
aggregated together for the purpose of determining the availability of any rights under this Agreement. 
  
 4.12 IPO. While the Company anticipates a successful completion to the Planned IPO, except as otherwise expressly provided herein,
no promise, representation or warranty has been made or given to PPD with regard thereto including, but not limited to, the timing, terms, ultimate completion or success of any such future IPO. Except as otherwise provided herein, PPD acknowledges
that in connection with the Planned IPO, stockholders, including PPD, will be required to enter into certain customary undertakings and/or agreements as required by the Company or its underwriter(s). In connection with the Planned IPO, PPD agrees to
execute the Waiver and Lock-up Agreement in the forms attached hereto as Exhibit A (PPD’s obligations under which shall be conditioned on: (a) all officers, directors, employees and 2% stockholders being subject to the same restrictions; and
(b) the sale of all of the PPD Original Investment Shares, as defined herein, in the Planned IPO) and agrees to consent to the amendment to the Company’s Articles of Incorporation in the form attached hereto as Exhibit B. 
  
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  

 In Witness Whereof, the parties have executed this Amended and Restated Investors’ Rights
Agreement on the day and year first set forth above. 
  

			
	“COMPANY”
	
	Accentia Biopharmaceuticals, Inc.
		
	By:	 	/s/ Francis E. O’Donnell, Jr.
	 	 	Francis E. O’Donnell, Jr.
	 	 	Chief Executive Officer
	
	“PPD”
	
	Pharmaceutical Product Development, Inc.
		
	By:	 	/s/ Fred N. Eshelman
	 	 	Fred N. Eshelman
	 	 	Chief Executive Officer

  

 ASSIGNMENT AND ASSUMPTION AGREEMENT 
  
 THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (the “Assignment Agreement”) is executed this 28th day of June 2005, by
and between Pharmaceutical Product Development, Inc., a North Carolina corporation (“Assignor”), PPD International Holdings, Inc. a Delaware corporation (“Assignee”) and Accentia Biopharmaceuticals, Inc., a Florida corporation
(the “Company”). 
  
 W I T N E S S E T H:

  
 WHEREAS, Assignor and the Company are parties to that
certain Amended and Restated Investors’ Rights Agreement dated as of January 7, 2005 (the “Rights Agreement”); and 
  
 WHEREAS, Assignee is a wholly owned subsidiary of Assignor; and 
  

WHEREAS, Assignor has agreed to assign to Assignee, and Assignee has agreed to assume, all of the rights and obligations of Assignor under the Rights
Agreement; and 
  
 WHEREAS, the Company has agreed to waive the
restriction on transfer contained in Section 1.13 of the Rights Agreement and permit the assignment. 
  
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally
bound, hereby agree as follows: 
  
 1. The recitals set forth
above are true and correct and are incorporated herein by reference. 
  
 2. Assignor hereby assigns to Assignee all of Assignor’s rights, duties and obligations under the Rights Agreement. 
  
 3. Assignee hereby accepts the assignment of Assignor and assumes all of the rights, duties and obligations of Assignor under the Rights Agreement and
agrees to perform all of such duties and obligations in accordance with the terms and provisions of the Rights Agreement as if Assignee had originally executed the Agreement. 
  
 4. As permitted by Section 4.1 of the Rights Agreement, the Company hereby consents to the assignment of all of
Assignor’s rights, duties and obligations under the Rights Agreement to the Assignee, such consent evidenced by the Company’s countersignature hereto. 
  

5. This Assignment Agreement shall inure to the benefit of and be binding upon the parties hereto and their successors and assigns. This Assignment
Agreement may be executed in one or more counterparts and each counterpart shall be deemed to be an original. 
  
 [The next page is the signature page.] 

 IN WITNESS WHEREOF, the parties have executed this Assignment Agreement as of the date first above
written. 
  

					
	ASSIGNOR:	 	PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
			
	 	 	By:	 	 /s/ B. Judd Hartman

	 	 	Name:	 	B. Judd Hartman
	 	 	Title:	 	General Counsel and Secretary
		
	BUYER:	 	PPD INTERNATIONAL HOLDINGS, INC.
			
	 	 	By:	 	 /s/ B. Judd Hartman

	 	 	Name:	 	B. Judd Hartman
	 	 	Title:	 	General Counsel and Secretary

  

			
	Acknowledged and Agreed to
	this 28th day of June 2005
	
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	By:	 	 /s/ James A. McNulty

	Name:	 	 
	Title:	 	Secretary

 ACCENTIA BIOPHARMACEUTICALS, INC. 
  
 AGREEMENT 
  
 WHEREAS, Accentia Biopharmaceuticals, Inc., a Florida corporation (the “Company”), is proposing to undertake an initial public offering of its
common stock, par value $.001 per share pursuant to a Registration Statement on Form S-1 originally filed on February 11, 2005, as amended (Registration No. 33-122769) (the “Planned IPO”). 
  
 WHEREAS, the undersigned, as assignee of Pharmaceutical Product Development,
Inc. (collectively, “PPD”), and the Company are parties to an Amended and Restated Investors’ Rights Agreement dated January 7, 2005 (the “Investors’ Rights Agreement”). 
  
 WHEREAS, to facilitate the Planned IPO, it is necessary to obtain the waiver
of certain rights held by the undersigned under the Investors’ Rights Agreement. 
  
 NOW, THEREFORE, for good and valuable consideration, including the continued pursuit of the Planned IPO by the Company, the parties make the following agreements: 
  
 1. PPD Original Investment Shares. The definition of “PPD
Original Investment Shares” as set forth in the fifth recital of the Investors’ Rights Agreement is hereby amended such that the fifth recital shall read in its entirety as follows: 
  
 “Whereas, the parties desire to set forth herein the terms under which
the Company agrees to include and sell in the Planned IPO all of the shares of Common Stock issuable to PPD, up to an amount equal to the lesser of (i) maximum gross proceeds to PPD of Twelve Million Dollars ($12,000,000) and (ii) One Million
(1,000,000) shares, which may be expanded in the discretion of the Underwriter and the Company (the “PPD Original Investment Shares”).” 
  
 2. No Other Amendment. All other terms of the Investors’ Rights Agreement shall continue in full force and effect. 
  
 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the
date set forth below. 
  

			
	 PPD INTERNATIONAL HOLDINGS, INC.

		
	 Name
	 	 /s/ Fred Davenport

	 Title:
	 	 Vice President

	 Date:
	 	 7-8-05

	
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	 Name
	 	 /s/ James A. McNulty

	 Title:
	 	 Secretary/Treasurer

	 Date:
	 	 7-8-05Accentia Assumption of Debt And Security Agreement

 Exhibit 10.39 
  
 ACCENTIA ASSUMPTION OF DEBT AND SECURITY AGREEMENT 
  
 THIS ACCENTIA ASSUMPTION OF DEBT AND SECURITY AGREEMENT (this
“Agreement”), dated as of December 31, 2003, is made and executed by and between ACCENTIA, INC., a Florida corporation (“Accentia”) and McKESSON CORPORATION, a Delaware corporation (“Secured
Party” or “McKesson”) pursuant to that certain “Forbearance Agreement” dated as of December 9, 2003 by and among, McKesson, Accentia and Accent Rx and is based on the Recitals set forth in said Forbearance
Agreement (all of which are incorporated herein by this reference), and also upon following facts and understandings: 
  
 WHEREAS, Accentia currently owns 100% of the stock in Accent Rx, a Florida corporation (“Accent Rx”) which was the successor to American
Prescription Providers, Inc., a Delaware corporation (“APP”). formerly a customer of and borrower from McKesson. 
  
 WHEREAS, contemporaneously with the acquisition by Accent Rx, Inc. of the assets and liabilities of APP effective October 21, 2002, pursuant to a purchase
agreement dated as of October 11, 2002, Accent Rx, Inc. as “Debtor” executed and delivered to McKesson that certain “Assumption of Debt and Security Agreement” dated as of October 29, 2002 (the “Accent Rx Assumption
Agreement”). Among the liabilities of APP assumed by Accent Rx were all obligations owed by APP to McKesson pursuant to that certain “Credit Agreement” executed on or about November 30, 1998 by APP and McKesson (the
“Credit Agreement”), and each of the other “Loan Documents” (as defined in the Credit Agreement) executed pursuant thereto or concurrently therewith, including a “McKesson Health Systems Agreement to Serve
American. Prescription Providers, Inc. as Prime Vendor of Pharmaceuticals” dated as of November 30, 1998 (the “Supply Agreement”), which Supply Agreement is also sometimes referred to in certain of the Loan Documents as a
“Wholesale Supply Agreement” The Credit Agreement, Loan Documents and Supply Agreement were duly modified and amended from time to time since November 30, 1998, including by a “Third Amendment to Credit Agreement” dated as of May
2, 2000. A true and correct copy of the Credit Agreement (including all amendments) is attached hereto as Exhibit A. Ensuing references herein to the “Credit Agreement,” the “Loan Documents,” and the “Supply
Agreement” shall be deemed to refer to such documents as amended from time to time in writing and executed by McKesson. 
  
 WHEREAS, McKesson obtained a duly perfected security interest of first priority in all assets of APP (and in those of all of its subsidiaries) pursuant,
among other things, to a Security Agreement dated as of November 30, 1998 between APP and McKesson, and pursuant to a “Subsidiary Security Agreement” executed as of November 30, 1998 by American Prescription Providers of Georgia, Inc.,
American Prescription Providers of Florida, Inc., and American Prescription Providers of New York, Inc. and by McKesson as “Secured Party” to secure the payment and performance of a “Subsidiary Guaranty” likewise dated as of
November 30, 1998 and executed by American Prescription Providers of Georgia, Inc., American Prescription Providers of Florida, Inc., and American Prescription Providers of New York, Inc. The Subsidiary Security Agreement and Subsidiary Guaranty
were duly amended from time to time, including on October 6, 1999 when American Prescription Providers of Pennsylvania, Inc. was added as a guarantor to the Subsidiary Guaranty and as a “Debtor” to the Subsidiary Security Agreement.

  

 WHEREAS, on or about November 30, 1998, Francis E. O’Donnell, Jr., M.D. and Dennis L. Ryll, M.D.
executed a “Principal Guaranty” for the benefit of McKesson guarantying the payment and performance of all existing and thereafter arising obligations of APP to McKesson relating to the Credit Agreement, the Supply Agreement, the
“Notes” executed pursuant to the Credit Agreement, and all of the other Loan Documents, up to a maximum, in the aggregate of $ 10,000,000 for principal, plus all interest thereon, and all costs and expenses relating to the enforcement of
the Principal Guaranty or the collection of the obligations owed by APP to McKesson. The Principal Guaranty, as it may have been amended in writing from time to time, and the Subsidiary Guaranty (to the extent any signatories thereto have not
dissolved) remain in full force, and effect in accordance with their express written terms, excepting that references therein to APP (by any name or designation, whether “borrower” or “debtor”, etc.) currently refers to Accent Rx
as the successor of APP. Francis E. O’Donnell, Jr., M.D. is a manager of Hopkins Capital Group, LLC (“HCG”). Dennis Ryll, MD is an officer of the general partner of MOAB Investments, LP (“MOAB”). MOAB and HCG,
together, own a majority interest in the outstanding common stock of Accentia, Inc., the parent and 100% shareholder of Accent Rx. Francis E. O’Donnell, Jr., M.D. is a manager of Hopkins Capital Group II, LLC (“HCG II”).

  
 WHEREAS, on or about November 19, 1999, McKesson received a
third party pledge from Regent Court Technologies (a limited liability company of which Francis E. O’Donnell, Jr., M.D. is the managing member) of 1,000,000 shares of stock in Star Scientific, Inc. (or a larger number if the value dips at any
time below $2,250,000) for the purpose of securing all obligations of Regent Court Technologies (hereafter, “RCT”), Francis E. O’Donnell, Jr., M.D., and/or APP (or its successor, Accent Rx) to McKesson. The third party pledge
agreement signed by RCT is included in the definition of “Loan Documents” and remains in full force and effect, excepting that references therein to APP (by any name or designation, whether “borrower” or “debtor”, etc.)
currently refers to Accent Rx as the successor of APP. 
  
 WHEREAS, when APP transferred all of its assets to Accent Rx (and when Accent Rx assumed all liabilities of APP), the assets conveyed by APP remained subject to the duly perfected, security interests in favor of McKesson securing all
obligations owing by APP to McKesson (the “APP Obligations”, including, without limitation, the sums owing under the loans referred to in the previous Recital (all of which APP Obligations were assumed by Accent Rx). Such security
interests were of first priority. 
  
 WHEREAS, APP and Accent Rx
represented to McKesson that (i) each of American Prescription Providers of New York, Inc., American Prescription Providers of Florida, Inc., American Prescription Providers of Georgia, Inc., and American Prescription Providers of Pennsylvania, Inc.
transferred all of their respective assets (if any) to either Accent Rx or APP (which then transferred those assets to Accent Rx), (ii) American Prescription Providers of Florida, Inc. has been administratively dissolved and wound up its affairs,
(iii) American Prescription Providers of Georgia, Inc. has dissolved, (iv) American Prescription Providers of New York, Inc. has been dissolved, and (v) American Prescription Providers of Pennsylvania, Inc. has not yet dissolved, but has ceased
operations, and is likely to dissolve or be dissolved in the near term. 
  

 2 

 WHEREAS, to induce McKesson not to declare a default and resort to its creditor’s rights and
remedies with regard to the APP Obligations and the collateral therefor due to the sale by APP of its assets to Accent Rx, (1) Accent Rx confirmed its assumption of all obligations owing to McKesson without defense or offset and formally granted to
McKesson a security interest in all existing and thereafter acquired assets of Accent Rx as provided in the Accent Rx Assumption Agreement, and (2) each of RCT, the signatories of the Principal Guaranty, and the signatories of the Subsidiary
Guaranty reaffirmed their obligations to McKesson, albeit substituting Accent Rx for APP as the obligor of the obligations guaranteed by them as guarantors or third party obligors. 
  
 WHEREAS, as of November 30, 2003, the components of the APP Obligations excluding the trade debt owing under the Supply
Agreement equaled the following: 
  

													
	 DEBT

	  	PRINCIPAL

	  	INTEREST

	  	FEES1 &
LATE
CHARGES

	  	TOTAL

	 1. Revolver
	  	$	2,202,182.36	  	$	103,294.93	  	$	30,005.05	  	$	2,335,482.34
	 2. Term Loan
	  	$	3,900,000.00	  	$	222,587.63	  	$	385,217.29	  	$	4,507,804.92
	 TOTAL:
	  	$	6,102,182.36	  	$	325,882.56	  	$	415,222.79	  	$	6,843,287.26

  
 Interest has accrued since November
30, 2003 on the principal amounts of the foregoing obligations at a per diem rate of $791.49, and will continue to do so until paid in full, assuming LIBOR rate stays at 1.1694%. The trade debt owing to McKesson by Accent Rx pursuant to the Supply
Agreement totaled $4,610,073 as of November 30, 2003 and is currently all due and payable. 
  
 WHEREAS, in mid-2003, Accentia approached McKesson and requested that McKesson loan to Accentia the sum of $2,500,000 with which Accentia would purchase not less than 81% of the outstanding shares in BioVest
International, Inc. (“BioVest”). McKesson loaned to Accentia $2,500,000.00 (the “Bridge Loan”), which Bridge Loan is evidenced by a promissory note dated as of June 12, 2003 (the “Bridge Note”), in
order to fund Accentia’s purchase of an 81% stake in BioVest. Concurrently with the execution of the Bridge Note, Accentia and certain of its affiliates executed in favor of McKesson certain security documents (together with the Bridge Note,
called the “Bridge Loan Documents”), including a “Third Party Pledge Agreement” executed by Hopkins Capital Group II, LLC (i.e., “HCG II”) as of June 12, 2003 and a “Stock Pledge Agreement”
executed by Accentia as of June 12, 2003. 

	1	 	Exclusive of attorneys’ fees and costs for which Accent Rx must reimburse McKesson.

  

 3 

 WHEREAS, on or about October 10, 2003, the “Third Party Pledge Agreement” dated as of June 12,
2003 and executed by HCG II was amended by that certain “First Amendment to Third Party Stock Pledge Agreement” executed by McKesson and HCG II. References to the Third Party Pledge Agreement signed by HCG II shall be deemed to refer to
said Third Party Pledge Agreement as amended by said First Amendment to Third Party Stock Pledge Agreement dated as of October 10, 2003. The collateral described in the Bridge Loan Documents (as amended) is defined as the “Bridge Loan
Collateral.” 
  
 WHEREAS, Accentia has requested that
McKesson (a) forbear from exercising its creditors’ rights and remedies with regard to certain obligations of Accentia as more particularly addressed in the Forbearance Agreement referenced above, (b) permit the sale of the assets of Accent Rx
to a third party (“Buyer”) free and clear of the liens and claims of McKesson on such assets relating to the APP Obligations, notwithstanding that the sale proceeds will not pay the obligations owed by Accent Rx to McKesson in full, and
(c) allow Accentia to assume the indebtedness still owing by Accent Rx to McKesson, subject to the modification of the repayment terms thereof. McKesson has set forth the terms upon which it is willing to forbear vis-a-vis Accentia (and Accent Rx,
for a limited period) and the terms upon which it will consent to the sale of the assets of Accent Rx in the Forbearance Agreement. McKesson is willing to accommodate the other request made by Accentia subject to the terms and conditions of this
Agreement, including that Accentia shall assume all obligations owed by Accent Rx to McKesson, including the APP Obligations. 
  
 NOW THEREFORE, for fair and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Accentia and McKesson hereby agree as
follows: 
  
 SECTION 1 Definitions: Interpretation.

  
 (a) All capitalized terms used in this Agreement and not
otherwise defined herein shall have the meanings assigned to them in the Credit Agreement. 
  
 (b) As used in this Agreement (including the Preamble hereof), the following terms shall have the following meanings: 
  
 “Accent Rx Debt Documents” means the Accent Rx Assumption Agreement, the Credit Agreement (as amended, including by the Third Amendment
to Credit Agreement), the other Loan Documents, the Supply Agreement, and any documents or agreements executed pursuant to any of them, as any may have been amended in writing from time to time. 
  
 “Assumed Indebtedness” means all indebtedness owing as of
the date hereof by Accent Rx to McKesson (or any affiliate of McKesson), whether liquidated or unliquidated, whether or not evidenced by a promissory note or other instrument, whether or not contingent, and whether or not specifically identified in
this Agreement or in the Accent Rx Debt Documents, including but no limited all of the APP Obligations previously assumed by Accent Rx., and all fees, costs and expenses for which Accent Rx was required to reimburse McKesson or any of
McKesson’s affiliates. 
  

 4 

 “BioVest” means Bio Vest International, Inc. (“BioVest”), the
corporation in which Accentia acquired 81% of the outstanding shares on a fully diluted basis using, in part, the proceeds of a “Bridge Note” payable to the order of McKesson by Accentia in the original principal amount of $2,500,000 and
dated as of June 12, 2003. 
  
 “Collateral” has
the meaning set forth in Section 4. 
  
 “Contract
Rate” means a rate of interest equal to ten percent (10%) per annum based on a 360-day year, for actual days elapsed. 
  
 “Credit Agreement” means that certain Credit Agreement referred to in the Recitals above as amended from time to time. 
  
 “Default Rate” means the rate interest accrues on the
Assumed Indebtedness after an Event of Default occurs equal to the Contract Rate plus 5%. 
  
 “Documents” means this Agreement, the Accent Rx Assumption Agreement, the Forbearance Agreement, the Bridge Loan Documents, the Loan Documents, the Supply Agreement, and all other certificates,
documents, agreements and instruments delivered at any time to Secured Party pursuant to or in connection with this Agreement, the Accent Rx Assumption Agreement, the Credit Agreement, the Supply Agreement (as any may have been or may be amended
from time to time in writing) or in connection with the Obligations, including any documents, agreements or certificates delivered to fulfill a Condition Subsequent defined in Section 26. 
  
 “Event of Default” has the meaning set forth in Section 12. 
  
 “Lien” means any mortgage, deed of trust, pledge, security
interest, assignment, deposit arrangement, charge or encumbrance, lien, or other type of preferential arrangement. 
  
 “Loans” means each of the “Revolving Loans,” the “Term Loan,” any sums financed under the Supply Agreement, the sums
still owing (if any) under the lease financing facility provided by McKesson to APP, and any other loan made by McKesson to APP, Accent Rx or Accentia, currently or (as to Accentia) in the future. 
  
 “Obligations” means: 
  
 (i) all presently existing indebtedness, liabilities and
other obligations of APP and/or Accent Rx to Secured Party (each and all of which have been and will be assumed by Accentia, subject to no defenses, counterclaims or offsets whatsoever), plus 
  
 (ii) all presently existing or hereafter arising
indebtedness, liabilities and other obligations of Accentia to Secured Party (including, but not limited to those formerly of APP and assumed first by Accent Rx and now by Accentia), 

  

 5 

 
in each case, whether created under, arising out of or in connection with this Agreement, the Accent Rx Assumption Agreement, the Credit Agreement, any of
the other Documents, the Forbearance Agreement, the Bridge Loan Documents (as that term is defined in the Forbearance Agreement), or otherwise, including, without limitation, all unpaid principal of any Loans, all interest accrued thereon, all fees
and all other amounts payable by Accent Rx or Accentia (or APP) to Secured Party thereunder or in connection therewith, or in connection with the Supply Agreement or any other contract in favor of Secured Party to which Accent Rx or Accentia (or
APP) is a party (including without limitation, the Bridge Loan Documents), and whether due or to become due, absolute or contingent, liquidated or unliquidated, determined or undetermined, and including interest that accrues after the commencement
by or against Accent Rx or Accentia (or APP) of any bankruptcy or insolvency proceeding naming the Accent Rx or Accentia (or APP) as debtor in such proceeding. 
  

“Permitted Lien” means (i) any Lien in favor of Secured Party; (ii) duly perfected Liens to secure purchase money indebtedness for the
purchase of equipment by Accentia in the ordinary course of its business so long as the Lien only encumbers the equipment that is purchased and only secures the purchase price thereof, and (iii) any existing duly perfected Lien on the assets of
Accentia (or Teamm Pharmaceuticals, Inc.) to secure the Senior Credit Facility. 
  
 “Person” means an individual, corporation, partnership, joint venture, trust, unincorporated organization, governmental agency or authority, or any other entity of whatever nature. 
  
 “Remaining Debt Due Date” shall be September 1,2004, provided
that if and only if (a) no default or Event of Default has occurred under this Agreement through September 1, 2004, and (b) Accentia pays to McKesson in cash in good, collected funds an “Extension Fee” of $39,000 on or before September
1, 2004, then “Remaining Debt Due Date” shall be extended until January 15, 2005. 
  
 “Senior Credit Facility” means that certain existing credit facility provided to Accentia by Harbinger Mezzanine Partners; LP which presently aggregates $5,000,000 in principal outstanding, but which
may be increased to equal as much as $13,000,000, for principal, in the future (but no more) and may be funded by a syndicate of lenders of which Harbinger Mezzanine Partners, LP is a member, and shall also include any replacement facility provided
by any lender or group of lenders, not affiliated with Accentia, which lender (or group of lenders) shall be satisfactory to McKesson and which replacement facility shall be made on terms and conditions satisfactory to McKesson. 
  
 “Subsidiary” means any of Teamm Pharmaceuticals, Inc., The
Analytica Group, Inc., BioVest and any other entity in which Accentia owns an equity interest in excess of 51% of all direct or indirect ownership interests. 
  
 “UCC” means the Uniform Commercial Code as the same may, from time to time, be in effect in the State of California. 
  

 6 

 (c) Where applicable and except as otherwise defined herein, terms used in this Agreement shall have the
meanings assigned to them in the UCC. 
  
 (d) In this Agreement,
(i) the meaning of defined terms shall be equally applicable to both the singular and plural forms of the terms defined; and (ii) the captions and headings are for convenience of reference only and shall not affect the construction of this
Agreement. 
  
 SECTION 2 Confirmation of Assumption of
Obligations of APP and Accent Rx. Accentia hereby acknowledges, agrees, represents and warrants to McKesson that each of the Recitals set forth at the outset of this Agreement is true and correct (and that there is no longer any opportunity to
contest the debt figures based on manifest error as was reserved in the Forbearance Agreement), and that Accentia has and hereby does assume each and every debt, obligation, and liability owed by APP and/or Accent Rx to McKesson of every kind or
nature, whether such debt, obligation, arid liability was known, unknown, liquidated, unliquidated, disclosed, or undisclosed, existing or contingent, and whether or not explicitly listed in the Recitals or evidenced by a promissory note.
Furthermore, Accentia has no known or unknown defenses, counterclaims, rights of offset or set off, recoupment, or any other causes of action against McKesson or any Person that would prevent or interfere with the full collection and enforcement by
McKesson of all such assumed debts, obligations, and liabilities, and/or the full enforcement of each of the Documents against Accentia as though it were “Borrower” or APP or Accent Rx in accordance with the express written terms of such
Documents as the same may be amended in writing from time to time. Accentia further acknowledges and agrees that there are no oral understandings between Accentia and McKesson and that any purported agreement with McKesson must be in writing and
signed by McKesson in order to be enforceable against McKesson. 
  
 SECTION 3 [Omitted]. 
  
 SECTION 4 Security
Interest 
  
 (a) As security for the payment and performance
of the Obligations, Accentia hereby grants to McKesson a security interest in all of Accentia’s right, title and interest in, to and under all of its personal property, wherever located and whether now existing or owned or hereafter acquired or
arising, including all accounts, chattel paper, commercial tort claims, deposit accounts, documents, equipment (including all fixtures), general intangibles, intellectual property, patents, trademarks, service marks, trade names, trade secrets,
customer lists, copyrights, payment intangibles, instruments, inventory, investment property (including all stock it holds in Teamm Pharmaceuticals, Inc., The Analytica Group, Inc. and Bio Vest Inc., hereafter called the “Subsidiary
Stock”), membership interests, letter-of-credit rights, money and all products, proceeds and supporting obligations of any and all of the foregoing (collectively, the “Collateral”). Notwithstanding the foregoing, except for
fixtures (to the extent covered by Article 9 of the UCC), such grant of a security interest shall not extend to, and the term “Collateral” shall not include, any asset which would be real property under the law of the jurisdiction in which
it is located. 
  

 7 

 (b) Anything herein to the contrary notwithstanding, (i) Accentia shall remain liable under any
contracts, agreements and other documents included in the Collateral, to the extent set forth therein, to perform, all of its duties and obligations thereunder to the same extent as if this Agreement had not been executed, (ii) the exercise by
Secured Party of any of the rights hereunder shall not release Accentia or Accent Rx (or APP) from any of its duties or obligations under such contracts, agreements and other documents included in the Collateral, and (iii) Secured Party shall not
have any obligation or liability under any contracts, agreements and other documents included in the Collateral by reason of this Agreement, nor shall Secured Party be obligated to perform any of the obligations or duties of Accentia (and/or those
of APP or Accent Rx) thereunder or to take any action to collect or enforce any such contract, agreement or other document included in the Collateral hereunder. 
  

(c) This Agreement shall create a continuing security interest in the Collateral which shall remain in effect until terminated in accordance with
Section 23 hereof. 
  
 (d) Accentia hereby authorizes Secured
Party to file (with or without Accentia’s signature), at any time and from time to time thereafter, all financing statements, assignments, continuation financing statements, termination statements, account control agreements, and other
documents and instruments, in form reasonably satisfactory to Secured Party, and take all other action, as Secured Party may reasonably request, to perfect and continue perfected, maintain the priority of or provide notice of the security interest
of Secured Party in the Collateral and to accomplish the purposes of this Agreement. Without limiting the generality of the foregoing, Accentia ratifies and authorizes the filing by Secured Party of any financing statements filed prior to the date
hereof. Accentia will cooperate with Secured Party in obtaining control (as defined in the UCC) of Collateral consisting of deposit accounts, investment property, letter of credit rights and electronic chatter paper. Accentia will join with Secured
Party in notifying any third party who has possession of any Collateral of Secured Party’s security interest therein and obtaining an acknowledgment from the third party that it is holding the Collateral for the benefit of Secured Party.
Accentia will not create any chattel paper without placing a legend on the chattel paper acceptable to Secured Party indicating that Secured Party has a security interest in the chattel paper. 
  
 (e) Accentia acknowledges and agrees that the security agreements granted in
this Section 4 shall be subject and junior to only those duly perfected security interests granted by Accentia to secure the Senior Credit Facility. 
  
 SECTION 5 Conditions Precedent to Bank Obligations. It shall be a condition precedent to the enforceability of each and every obligation of
McKesson hereunder, including the obligations set forth in Section 6 below, that each and all of the following shall be and remain satisfied on or before December 15, 2003: 
  
 (a) This Agreement. McKesson shall have received an original counterpart of this Agreement, duly executed by
Accentia. 
  
 (b) Forbearance Agreement. McKesson shall
have received an original counterpart of the Forbearance Agreement, duly executed by Accentia and Accent Rx, and all conditions precedent to the effectiveness of the Forbearance Agreement shall have been satisfied. 
  

 8 

 (c) New Security Agreements. 
  
 i) RCT and HCG II shall have duly executed and delivered to McKesson a security agreement (the “New HCG
II/RCT Security Agreement”) in substantially the form of Exhibit B attached hereto granting to McKesson (or confirming the grant to McKesson) of a lien of first priority in certain marketable securities more specifically described
therein, which in the aggregate shall have a value of at least $8 million as of the execution and delivery of this Assumption Agreement to McKesson, which stock shall include any such stock previously pledged to McKesson, including under the Bridge
Loan Documents, subject to the following: in the event that BioVest becomes a publicly traded company, Accentia shall have the right, so long as no Event of Default has occurred and is continuing, to substitute $10,000,000 million worth of
unrestricted BioVest common stock for said marketable securities pledged to McKesson as collateral for the remaining indebtedness owed by Accentia to McKesson. To effect such substitution (and as a further condition to such substitution), Accentia
shall have delivered to McKesson a duly executed pledge agreement in form and substance satisfactory to McKesson relating to such stock of BioVest, shall have paid all fees and costs (including attorneys’ fees) associated with documenting the
substitution and satisfying the conditions to effectuating the substitution, shall have paid to McKesson any sums payable by HCG II or RCT to McKesson under the terms of the New HCG II/RCT Security Agreement, and shall have taken all steps necessary
(including physical delivery of the stock and delivery of stock powers signed in blank) such that upon substitution, McKesson shall have a duly perfected security interest of no less than first priority in all such BioVest stock. Upon the
satisfaction of all such conditions, including (but not limited to) that McKesson has a duly perfected security interest of no less than first priority in the common stock of BioVest after BioVest has become a publicly traded company, and provided
no Event of Default has occurred, and that McKesson has been reimbursed for all fees and costs (including attorneys’ fees) incurred in connection with such substitution of collateral and the satisfaction of the conditions to substitution,
McKesson will release the Pledged Collateral described in this Agreement from the lien in favor of McKesson. 
  
 ii) McKesson shall have received a security agreement (the “New HCG/MOAB Security Agreement”) in substantially the form of
Exhibit K attached hereto duly executed by HCG, MOAB and any subsidiaries of either of them with any interest in the stock of Accentia, pursuant to which security agreement McKesson shall be granted of a lien of first priority in all stock in
Accentia that is (or becomes) directly or indirectly owned or controlled by HCG or MOAB. 
  
 (d) Reaffirmation by Guarantors and Third Party Pledgors. Each of Francis E. O’Donnell, Jr., M.D., Dennis L. Ryll, M.D., HCG II, RCT and the other signatories thereto shall have executed the “Consent,
Reaffirmation and Release Agreement” in the form of Exhibit C attached hereto (the “Reaffirmation Agreement”), reaffirming their respective obligations under the Principal Guaranty and/or their third party pledge
agreements and acknowledging that the same remain in full force and effect with respect to the Obligations arid notwithstanding the assumption by Accentia of the APP Obligations and the other obligations owed by Accent Rx to McKesson. 
  

 9 

 (e) Interest Payment. McKesson shall have received payment in full of all interest that has
accrued from and after December 31,2003 through January 31,2004 on the Assumed Indebtedness at the rate applicable as provided in this Agreement. 
  
 (f) Borrowing Resolution. Each of Accentia, Teamm Pharmaceuticals, Inc. and The Analytica Group, Inc. shall have delivered to McKesson duly
executed resolutions of their respective Boards of Directors evidencing the power and authority of the person signing this Agreement and/or any other document executed pursuant hereto by any of Accentia, Teamm Pharmaceuticals, Inc. and The Analytica
Group, Inc. on behalf of the relevant entity to bind the corporation. 
  
 (g) Capitalization Table. Accentia shall have delivered to McKesson a capitalization table which discloses fully and accurately all direct and indirect ownership of Teamm Pharmaceuticals, Inc., The Analytica Group, Inc., BioVest
International, Inc., Accentia, Inc., HCG and MOAB. Said table shall be attached hereto as Exhibit E. 
  
 (h) [Intentionally omitted]. 
  
 (i) New Subsidiary Guaranties. Each of Teamm Pharmaceuticals, Inc. and The Analytica Group, Inc. shall have duly executed and delivered to McKesson
a guaranty of all obligations of Accentia to McKesson (the “New Subsidiary Guaranty”) in substantially the form of Exhibit F attached hereto. 
  

(j) New Subsidiary Security Agreements. Each of Teamm Pharmaceuticals, Inc. and The Analytica Group, Inc. shall have duly executed and delivered
to McKesson a security agreement, encumbering all their respective assets and securing the timely payment and performance of their respective obligations under the New Subsidiary Guaranty (the “New Subsidiary Security Agreement”) in
substantially the form of Exhibit G attached hereto, and McKesson shall be, and hereby is authorized to file such UCC-1 financing statements as are necessary or appropriate to perfect McKesson’s security interest in the collateral
described in each of the New Subsidiary Security Agreements. In addition, the security interests in the assets of The Analytica Group, Inc. and/or Teamm Pharmaceuticals, Inc. shall be junior only to Permitted Liens as defined in the New Subsidiary
Security Agreement). 
  
 (k) [Intentionally omitted.] 

 
 (1) Perfection in Stock of Subsidiaries. McKesson shall have
received possession and/or control of the Subsidiary Stock. 
  
 (m) Receipt of $4,000,000 from Sale of Accent Rx. On the earlier to occur of December 15,2003, and the closing date of the sale of all assets of Accent Rx (as was permitted subject to the terms and conditions of the Forbearance
Agreement), McKesson shall have received a payment equal to the greater of: (x) the entire proceeds received as of that date by Accentia from the sale of the assets of Accent Rx, and (y) $4,000,000, 
  

 10 

 (n) [Intentionally omitted.] 
  
 (o) Fees and Costs. McKesson shall have received payment in full of all fees expenses, and costs (including
attorneys’ fees and costs) incurred in negotiating and documenting this Agreement, the Forbearance Agreement, the Bridge Loan Documents, all other agreements and documents executed pursuant to any of the foregoing or concurrently with any of
the foregoing, as well as the fees, costs and expenses incurred by McKesson in the preparation of any proposal letters or term sheets relating to Accent Rx, Accentia, or any indebtedness assumed or incurred by either of them. 
  
 SECTION 6 Modification of Repayment Terms for Assumed Indebtedness.
Subject to the satisfaction of the conditions precedent set forth in Section 5 above, McKesson agrees to substitute the following payment schedule for the payment schedule that otherwise was operative under the Accent Rx Debt Documents (as to which
former payment schedule, Accent Rx was in default), provided that interest shall be payable as set forth in Section 7 below: 
  
 (a) Remaining Term Debt. By no later than June 28,2004, all indebtedness relating to the Accent Rx Debt Documents (all of which obligations shall
have been assumed by Accentia), all other Assumed Indebtedness, and any other interest bearing indebtedness of Accentia of any kind owed to McKesson (or any affiliate of McKesson) shall have been paid down in full, with the exception of no more than
$3,900,000 which amount shall constitute the remaining principal of the term debt obligations assumed by Accentia and, which remaining debt shall be referred to herein as the “Remaining Term Debt”. 
  
 (b) Payment of Remaining Term Debt. The Remaining Term Debt, plus
accrued and unpaid interest on the principal portion thereof, together with any fees, costs and expenses incurred by McKesson in connection with the Assumed Indebtedness, this Agreement, or any other indebtedness of Accentia (or Accent Rx) to
McKesson (or to any affiliate of McKesson), or in connection with the collateral therefor (for all of which Accentia must reimburse McKesson), shall be paid in full (subject to Section 6(c) below) on or before the Remaining Debt Due Date (unless and
to the extent McKesson converts any portion thereof to equity, which McKesson may elect to do in its sole and absolute discretion on terms no less favorable than the proposed Series E financing that Accentia expects to obtain in 2003, all as more
particularly set forth in Section 25 below). 
  
 (c) Potential
Credit Against Remaining Term Debt. So long as no Event of Default has occurred and Accentia has paid all of the Remaining Debt, plus interest, fees and costs as and when due, then on the Remaining Debt Due Date (or on any earlier date) when
Accentia is prepared to pay all outstanding sums owing to McKesson by Accentia under this Agreement or otherwise, Accentia may hold back from such final payment in full the sum of $400,000 which shall be deemed attributable to the fees and late
charges that have accrued through November 30, 2003 as reflected in the Recitals set forth above. The $400,000 debt related to the $400,000 payment held back by Accentia shall remain outstanding, but shall not accrue interest. If after 91 days from
such date of final and complete payment, (i) Accentia has not become a debtor in a case under title 11 of the United States Code (the “Bankruptcy Code”), (ii) McKesson has been able to retain all payments received from Accentia or on
account of the indebtedness owed by Accentia, and (iii) none of the payments is the subject of any actions to 

  

 11 

 
avoid such payments or to recover them as a fraudulent transfer, preferential payment or otherwise regardless of whether in the context of a
bankruptcy, then such $400,000 remaining debt shall be forgiven. 
  
 SECTION 7 Interest on Assumed Obligations. 
  
 (a)
From and after the date hereof, but prior to the occurrence of an Event of Default, interest shall accrue on the principal portion of the Assumed Indebtedness at a rate per annum equal to the Contract Rate, based on a 360-day year for actual days
elapsed. After the occurrence of an Event of Default, interest shall accrue on the principal portion of all obligations. owing by Accentia to McKesson (or to any affiliate of McKesson) at a rate equal to the Default Rate, based on a 360-day year for
actual days elapsed. In the absence of acceleration after an Event of Default, accrued interest shall be payable to McKesson (or the applicable affiliate, if any) monthly in arrears on the first business day of each calendar month for the previous
month ending commencing with December 1, 2003. 
  
 (b) In no event
shall the interest rate or rates payable under this Agreement the Forbearance Agreement or in connection with the Assumed Indebtedness, plus any other amounts paid in connection herewith, exceed the highest rate permissible under any law that a
court of competent jurisdiction shall, in a final determination, deem applicable. Accentia and McKesson, in executing this Agreement, the Forbearance Agreement and the other Documents, intend legally to agree upon the rate or rates of interest and
manner of payment stated within it; provided, however, that, anything contained herein or in any Document to the contrary notwithstanding, if said rate or rates of interest or manner of payment exceeds the maximum allowable under applicable law,
then, ipso facto as of the date of this Agreement and/or such other Document, Accentia is and shall be liable only for the payment of such maximum as allowed by law, and payment received from Accentia in excess of such legal maximum, whenever
received, shall be applied to reduce the principal balance of the Obligations to the extent of such excess. 
  
 SECTION 8 Representations and Warranties. Accentia represents and warrants to McKesson that: 
  
 (a) Accentia is a corporation duly organized, validly existing and in good
standing under the laws of the state of Florida and has all requisite power and authority to execute, deliver and perform its obligations under this Agreement. 
  

(b) The execution, delivery and performance by Accentia of this Agreement have been duly authorized by all necessary action of Accentia and its Board
of Directors, and this Agreement constitutes the legal, valid and binding obligation of Accentia, enforceable against Accentia in accordance with its terms. 
  
 (c) No authorization, consent, approval, license, exemption of, or filing or registration with, any governmental authority or agency, or approval or
consent of any other Person, is required for the due execution, delivery or performance by Accentia of this Agreement, except for any filings necessary to perfect any Liens on any Collateral. 
  

 12 

 (d) Accentia’s chief executive office and principal place of business (as of the date of this
Agreement) is located at the address set forth in Schedule 1; Accentia’s exact legal name is as set forth in the first paragraph of this Agreement; and all other locations where Accentia conducts business or Collateral is kept (as of the
date of this Agreement) are set forth in Schedule 1. 
  
 (e) Schedule 1 also accurately sets forth the proper names (as reflected in their official formation or registration documentation as filed with the appropriate office of their jurisdictions of organization), jurisdictions of
organization, and chief executive offices of each, of HCG, HCG II, RCT, Accent Rx, BioVest, Teamm Pharmaceuticals, Inc., and The Analytica Group, Inc. 
  
 (f) Accentia has rights in or the power to transfer the Collateral, and Accentia is the sole and complete owner of the Collateral, free from any Lien
other than Permitted Liens. 
  
 (g) All of the U.S. and foreign
patents and patent applications, copyrights (whether or not registered), applications for copyright, trademarks, service marks and trade names (whether registered or unregistered), and applications for registration of such trademarks, service marks
and trade names, which are owned by any of Accentia, Accent Rx, Teamm Pharmaceuticals, Inc., The Analytica Group, Inc., HCG and RCT are set forth in Schedule 2. 
  
 (h) Accentia is not and will not become a lessee under any real property lease or other agreement governing the location of
Collateral at the premises of another Person pursuant to which the lessor or such other Person may obtain any rights in any of the Collateral, and no such lease or other such agreement now prohibits, restrains, impairs or will prohibit, restrain or
impair such Accentia’s right to remove any Collateral from the premises at which such Collateral is situated, except for the usual and customary restrictions contained in such leases of real property. 
  
 (i) No control agreements exist with respect to any Collateral other than
control agreements in favor of Secured Party. 
  
 (j) Accentia
does not have or hold any chattel paper, letter-of-credit rights or commercial tort claims except as disclosed to Secured Party. 
  
 (k) The names and addresses of all financial institutions and other Persons at which Accentia, Accent Rx, Teamm Pharmaceuticals, Inc., and/or The
Analytica Group, Inc. maintains a deposit and securities accounts, and the account numbers and account names of such accounts, are set forth in Schedule 1. 
  
 SECTION 9 Covenants. So long as any of the Obligations remain unsatisfied, Accentia agrees that: 
  
 (a) Accentia shall deliver to McKesson not later than the 30th day after each fiscal quarter consolidated income statements, balance sheets and statements of cash flow, each prepared in
accordance with GAAP. 
  

 13 

 (b) Accentia shall, deliver to McKesson a copy of any and all reports, statements, business plans, and
other documentation, which it provides to any of its shareholders or to the members of its Board of Directors and such deliveries to McKesson shall be contemporaneous with the deliveries to such shareholders or Board members. 
  
 (c) Accentia shall appear in and defend any action, suit or proceeding which
may affect to a material extent its title to, or right or interest in, or McKesson’s right or interest in, the Collateral, and shall do and perform all reasonable acts that may be necessary and appropriate to maintain, preserve and protect the
Collateral. 
  
 (d) Accentia shall comply in all material respects
with all laws, regulations and ordinances, and all policies of insurance, relating in a material way to the possession, operation, maintenance and control of the Collateral. 
  
 (e) Accentia shall give 15 days’ prior written notice to McKesson before making: 
  
 i) Any change in the location of Accentia’s chief
executive office or principal place of business and any change in the location of the chief executive office or principal place of business of any of its Subsidiaries; 
  
 ii) any change in the locations set forth in Schedule 1; 
  
 iii) any change in its name or that of any Subsidiary;

  
 iv) any changes in its identity or structure
or that of any Subsidiary in any manner which might make any financing statement filed hereunder (or under any of the documents executed pursuant hereto) incorrect or misleading; 
  
 v) any change in its registration as an organization (or any new such registration) or any change in the
registration of any Subsidiary as an organization (or any new such registration); or 
  
 vi) any change in its jurisdiction of organization or that of any Subsidiary; 
  
 provided that Accentia shall not locate any Collateral outside of the United States
nor shall Accentia (or any subsidiary) change its jurisdiction of organization to a jurisdiction outside of the United States. 
  
 (f) Accentia shall carry and maintain in full force and effect, at its own expense and with financially sound and reputable insurance companies, insurance
with respect to the Collateral in such amounts, with such deductibles and covering such risks as is customarily carried by companies engaged in the same or similar businesses and owning similar properties in the localities where Accentia operates.
Insurance on the Collateral shall name Secured Party as additional insured and as loss payee. Upon the request of Secured Party, Accentia shall furnish Secured Party from time to time with full information as to the insurance carried by it and, if
so requested, copies of all such insurance policies. Accentia shall also furnish to Secured Party at 

  

 14 

 
least once in each calendar year a certificate of Accentia’s insurance broker or other insurance specialist stating that all premiums then due on the
policies relating to insurance on the Collateral have been paid and that such policies are in full force and effect. All insurance policies required under this subsection (f) shall provide that they shall not be terminated or cancelled nor shall any
such policy be materially changed without at least 30 days’ prior written notice to Accentia and Secured Party. Receipt of notice of termination or cancellation of any such insurance policies or reduction of coverage’s or amounts
thereunder shall entitle Secured Party to renew any such policies, cause the coverage’s and amounts thereof to be maintained at levels required pursuant to the first sentence of this subsection (f) of otherwise to obtain similar insurance in
place of such policies, in each case at the expense of Accentia. 
  
 (g) All insurance policies shall provide that any losses payable thereunder be payable directly to Secured Party unless written authority to the contrary is obtained. In the event that Accentia shall receive any proceeds of any insurance
(other than in respect of third party liability insurance) it shall immediately cause such proceeds to be paid over to Secured Party. If the Collateral shall be materially damaged or destroyed, in whole or in part, by fire or other casualty,
Accentia shall give prompt notice thereof to Secured Party. Additionally, Accentia shall in any event promptly give Secured Party notice of all reports made to insurance companies in respect of any claim in excess of $10,000. No settlement on
account of any loss covered by insurance shall be made for less than insured value without the consent of Secured Party. In its sole and absolute discretion Secured Party may apply all or any portion of such insurance proceeds to the payment of
Obligations or may release all or any portion thereof to Accentia. 
  
 (h) Accentia shall keep separate, accurate and complete books and records with respect to the Collateral, disclosing Secured Party’s security interest hereunder. 
  
 (i) Accentia shall not surrender or lose possession of (other than to Secured Party), sell, lease, rent, or otherwise
dispose of or transfer any of the Collateral or any right or interest therein, except in the ordinary course of business or unless such Collateral is replaced by comparable Collateral of similar value; provided that no such disposition or
transfer of Collateral consisting of investment property or instruments shall be permitted while any Event of Default exists. 
  
 (j) Accentia shall keep the Collateral free of all Liens except Permitted Liens. 
  
 (k) Accentia shall pay and discharge all taxes, fees, assessments and governmental charges or levies imposed upon it with
respect to the Collateral prior to the date on which penalties attach thereto, except to the extent such taxes, fees, assessments or governmental charges or levies are being contested in good faith by appropriate proceedings. 
  
 (l) Accentia shall maintain and preserve its legal existence, its rights to
transact business and all other rights, franchises and privileges necessary or desirable in the normal course of its business and operations and the ownership of the Collateral, except in connection with any transactions expressly permitted by the
Credit Agreement or any other Document. 
  

 15 

 (m) Upon the request of Secured Party, Accentia shall (i) immediately deliver to Secured Party, or an
agent designated by it, appropriately endorsed or accompanied by appropriate instruments of transfer or assignment, all documents and instruments, all certificated securities with respect to any investment property, all letters of credit and all
accounts and other rights to payment at any time evidenced by promissory notes, trade acceptances or other instruments, (ii) cause any securities intermediaries to show on their books that Secured Party is the entitlement holder with respect to any
investment property, and/or obtain account control agreements in favor of Secured Party from such-securities intermediaries, in form and substance satisfactory to Secured Party, with respect to any investment property, as requested by Secured Party,
(iii) provide such notice, obtain such acknowledgments and take all such other action, with respect to any chattel paper, documents and letter-of credit rights, as Secured Party shall reasonably specify, and (iv) obtain consents from any letter of
credit issuers with respect to the assignment to Secured Party of any letter of credit proceeds. 
  
 (n) Accentia shall at any reasonable time and from time to time permit Secured Party or any of its agents or representatives to visit the premises of
Accentia and inspect the Collateral and to examine and make copies of and abstracts from the records and books of account of Accentia. 
  
 (o) Accentia shall: (i) with such frequency as Secured Party may require, furnish to Secured Patty such lists of customers and other information relating
to the accounts and other rights to payment as Secured Party shall reasonably request (which information Secured Party agrees to treat as confidential so long as doing so would not interfere with the rights of Secured Party as a secured creditor or
its ability to assign participations or interests in the Loans or the other Documents to third parties consistent with the provisions of the other Documents); (ii) give only normal discounts, allowances and credits as to accounts and other rights to
payment, in the ordinary course of business, according to normal trade practices utilized by Accentia, and enforce all accounts and other rights to payment strictly in accordance with their terms, except that Accentia may grant any extension of the
time for payment or enter into any agreement to make a rebate or otherwise to reduce the amount owing on or with respect to, or compromise or settle for less than the full amount thereof, any account or other right to payment, in the ordinary course
of business, according to normal and prudent trade practices utilized by Accentia; and (iii) upon the request of Secured Party (A) at any time, notify all or any designated portion of the account debtors and other obligors on the accounts and other
rights to payment of the security interest hereunder, and (B) upon the occurrence and during the continuance of an Event of Default, notify the account debtors and other obligors on the accounts and other rights to payment or any designated portion
thereof that payment shall be made directly to Secured Party or to such other Person or location as Secured Party shall specify. 
  
 (p) Accentia shall (i) notify Secured Party of any material claim made or asserted against the Collateral by any Person and of any change in the
composition of the Collateral or other event which could materially adversely affect the value of the Collateral or Secured Party’s Lien thereon; (ii) furnish to Secured Party such statements and schedules further identifying and describing the
Collateral and such other reports and other information in connection with the Collateral as Secured Party may reasonably request, all in reasonable detail; and (iii) upon reasonable request of Secured Party make such demands and requests for
information and reports as Accentia is entitled to make in respect of the Collateral, provided that none of the foregoing need be duplicative of other reports prepared and provided to Secured Party pursuant to the other 

  

 16 

 
Documents, provided that Accentia identifies for Secured Party where the requested information can be located in the existing reports. 
  
 (q) If and when Accentia shall obtain rights to any new patents, trademarks,
service marks, trade names or copyrights, or otherwise acquire or become entitled to the benefit of, or apply for registration of, any of the foregoing, Accentia (i) shall promptly notify Secured Party thereof and (ii) hereby authorizes Secured
Party to modify, amend, or supplement any schedules, exhibits, or certificates provided in connection with any of the Documents and relating to any Collateral and from time to time to include any of the foregoing and make all necessary or
appropriate filings with respect thereto. 
  
 (r) Accentia shall
not, without the prior written consent of McKesson, which consent shall not be unreasonably withheld, enter into any agreement (including any license or royalty agreement) pertaining to any of its patents, copyrights, trademarks, service marks and
trade names, except for non-exclusive licenses in the ordinary course of business. 
  
 (s) At Secured Party’s request, Accentia will obtain from each Person from whom Accentia leases any premises at which any Collateral is at any time present such collateral access, subordination, waiver, consent
and estoppel agreements as Secured Party may require, in form and substance satisfactory to Secured Party. 
  
 (t) Accentia shall give Secured Party immediate notice of the acquisition of any i instruments or securities, or the establishment of any new deposit
account or any new securities account with respect to any investment property. 
  
 (u) Accentia shall immediately notify Secured Party if Accentia holds or acquires (i) any commercial tort claims, (ii) any chattel paper, including any interest in any electronic chattel paper, or (iii) any
letter-of-credit rights. 
  
 SECTION 10 Collection of
Accounts. Until Secured Party exercises its rights hereunder to collect the accounts and other rights to payment, Accentia shall endeavor in the first instance diligently to collect all amounts due or to become due on or with respect to the
accounts and other rights to payment. At the request of Secured Party, upon the occurrence and during the continuance of any Event of Default, all remittances received by Accentia shall be held in trust for Secured Party and, in accordance with
Secured Party’s instructions, remitted to Secured Party or deposited to an account of Secured Party in the form received (with any necessary endorsements or instruments of assignment or transfer). At the request of Secured Party, upon and after
the occurrence of any Event of Default, Secured Party shall be entitled to receive all distributions and payments of any nature with respect to any investment property or instruments, and all such distributions or payments received by Accentia shall
be held in trust for Secured Party and, in accordance with Secured Party’s instructions, remitted to Secured Party or deposited to an account with Secured Party in the form received (with any necessary endorsements or instruments of assignment
or transfer). Following the occurrence of an Event of Default, any such distributions and payments with respect to any investment property held in any securities account shall be held and retained in such securities account, in each case as part of
the Collateral hereunder. Additionally, Secured Party shall have the right, upon the occurrence of an Event of Default, without prior notice to Accentia, to vote and to give consents, ratifications and 

  

 17 

 
waivers with respect to any investment property and instruments, and to exercise all rights of conversion, exchange, subscription or any other rights,
privileges or options pertaining thereto, as if Secured Party were the absolute owner thereof; provided that Secured Party shall have no duty to exercise any of the foregoing rights afforded to it and shall not be responsible to Accentia or
any other Person for any failure to do so or delay in doing so. 
  
 SECTION 11 Authorization; Secured Party Appointed Attorney-in-Fact. 
  
 Secured Party shall have the right to, in the name of Accentia, or in the name of Secured Party or otherwise, upon notice to but without the requirement of assent by Accentia, and Accentia hereby constitutes and
appoints Secured Party (and any of Secured Party’s officers, employees or agents designated by Secured Party) as Accentia’s true and lawful attorney-in-fact, with full power and authority to: (i) sign and file any of the financing
statements and other documents and instruments which must be executed or filed to perfect or continue perfected, maintain the priority of or provide notice of Secured Party’s security interest in the Collateral (including any notices to or
agreements with any securities intermediary); (ii) assert, adjust, sue for, compromise or release any claims under any policies of insurance; (iii) give notices of control, default or exclusivity (or similar notices) under any account control
agreement or similar agreement with respect to exercising control over deposit accounts or securities accounts; and (iv) execute any and all such other documents and instruments, and do any and all acts and things for and on behalf of Accentia,
which Secured Party may deem reasonably necessary or advisable to maintain, protect, realize upon and preserve the Collateral and Secured Party’s security interest therein and to accomplish the purposes of this Agreement. Secured Party agrees
that, except upon and during the continuance of an Event of Default, it shall not exercise the power of attorney, or any rights granted to Secured Party, pursuant to clauses (ii), (iii) and (iv). The foregoing power of attorney is coupled with an
interest and irrevocable so long as the Obligations have not been paid and performed in full. Accentia hereby ratifies, to the extent permitted by law, all that Secured Party shall lawfully and in good faith do or cause to be done by virtue of and
in compliance with this Section 11. 
  
 SECTION 12 Events of
Default. Any of the following events which shall occur and be continuing shall constitute an “Event of Default”: 
  
 (a) Any Event of Default under the Credit Agreement or any of the Documents shall occur where the term “Borrower” (or “APP” or
“Accent Rx”) shall be deemed to refer to Accentia. 
  
 (b) Accentia shall fail to pay as and when due any payment required to be made pursuant to Section 7 of this Agreement or any other provision of this Agreement, or shall fail to pay when due any of the other Obligations, including but not
limited to the APP Obligations, all of which have been assumed by Accentia. 
  
 (c) Any breach of any material covenant or condition (or the failure of a Condition Subsequent defined in Section 26 to be timely satisfied) shall occur under this Agreement, any Document, the Forbearance Agreement or
any document or agreement executed pursuant to or concurrently with any of them. 
  

 18 

 (d) Any representation or warranty made by Accentia under or in connection with this Agreement or any
Document, shall prove to have been incorrect in any material respect when made or deemed made. 
  
 (e) Accentia or any Subsidiary shall admit in writing its inability to, or shall fail generally or be generally unable to, pay its debts (including its payroll) as such debts become due, or shall make a general
assignment for the benefit of creditors; or Accentia or any Subsidiary (or Accent Rx or APP) shall file a voluntary petition in bankruptcy or a petition or answer seeking reorganization, to effect a plan or other arrangement with creditors or any
other relief under the Bankruptcy Reform Act of 1978, as amended or recodified from time to time (the “Bankruptcy Code”) or under any other state or federal law relating to bankruptcy or reorganization granting relief to debtors, whether
now or hereafter in effect, or shall file an answer admitting the jurisdiction of the court and the material allegations of any involuntary petition filed against Accentia, any Subsidiary, Accent Rx, or APP, as the case may be or pursuant to the
Bankruptcy Code or any such other state or federal law; or Accentia or any Subsidiary (or Accent Rx or APP) shall be adjudicated a bankrupt, or shall make an assignment for the benefit of creditors, or shall apply for or consent to the appointment
of any custodian, receiver or trustee for all or any substantial part of Accentia’s property (or that of any Subsidiary, Accent Rx or APP), or shall take any action to authorize any of the actions set forth above in this paragraph; or an
involuntary petition seeking any of the relief specified in this paragraph shall be filed against Accentia or any Subsidiary (or Accent Rx or APP); or any order for relief shall be entered against Accentia or any Subsidiary (or Accent Rx or APP) in
any involuntary proceeding under the Bankruptcy Code or any such other state or federal law referred to in this subsection (e). 
  
 (f) Accentia or any Subsidiary shall (i) liquidate, wind up or dissolve (or suffer any liquidation, wind-up or dissolution), except to the extent
expressly consented to by Secured Party in writing, (ii) suspend its operations other than in the ordinary course of business, or (iii) take any action to authorize any of the actions or events set forth above in subsections (e) or (f). 

 
 (g) Any material impairment in the value of the Collateral described in
this Agreement (or the “Collateral” described in any New Subsidiary Security Agreement or in any third party pledge agreement) or in the priority of McKesson’s lien or security interest therein. 
  
 (h) Any levy upon, seizure or attachment of any of the Collateral described
in this Agreement (or the “Collateral” described in any New Subsidiary Security Agreement or in any third party pledge agreement), which shall not have been rescinded or withdrawn. 
  
 (i) Any loss, theft or substantial damage to, or destruction of, any material
portion of the Collateral described in this Agreement (or the “Collateral” described in any New Subsidiary Security Agreement or in any third party pledge agreement) (unless within 10 days after the occurrence of any such event, Accentia
furnishes to McKesson evidence satisfactory to McKesson that the amount of any such loss, theft, damage to or destruction of the Collateral or other collateral is fully insured under policies naming McKesson as the sole additional named insured or
loss payee). 
  

 19 

 (j) Any existing or future guarantor or third party pledgor of collateral to “ McKesson to secure or
guaranty the payment and performance of the Obligations (including, but not limited to, any Subsidiary, Francis E. O’Donnell, Jr., M.D., Dennis L. Ryll, M.D. [unless and until, in the case of Dr. Ryll, after the effectiveness of any release
from his liability under the Principal Guaranty], HCG, HCG II, or RCT) shall seek to revoke their guaranty or pledge, or shall repudiate their guaranty or pledge for any reason, including, without limitation, because their pledge or guaranty was of
the obligations owed by APP or Accent Rx rather than Accentia or Accent Rx, or any existing or future guarantor or third party pledgor shall die, cease to exist, become incompetent, or dissolve, or any existing or future guarantor or third party
pledgor shall become a debtor in a case under the Bankruptcy Code, or shall make a general assignment for the benefit of creditors or suffer any of the events to exist as to themselves that are described in subsections 9(e) or (f) with respect to
Accentia, provided that it shall hot constitute an Event of Default under this Agreement if APP and/or any of the subsidiaries of APP which guarantied the APP Obligations are dissolved, if and only if any liabilities of such entities
owed to McKesson have been assumed by Accentia. 
  
 SECTION 13
Remedies. 
  
 (a) Upon the occurrence and continuance of
any Event of Default, Secured Party may declare any or all of the Obligations to be immediately due and payable and shall have, in addition to all other rights and remedies granted to it in this Agreement, the Credit Agreement or any other Document
(where Accentia is treated as though it were the “Borrower” or APP), all rights and remedies of a secured party under the UCC and other applicable laws. Without limiting the generality of the foregoing, (i) Secured Party may peaceably and
without notice enter any premises of Accentia, take possession of any the Collateral, remove or dispose of all or part of the Collateral on any premises of Accentia or elsewhere, or, in the case of equipment, render it nonfunctional, and otherwise
collect, receive, appropriate and realize upon all or any part of the Collateral, and demand, give receipt for, settle, renew, extend, exchange, compromise, adjust, or sue for all or any part of the Collateral, as Secured Party may determine; (ii)
Secured Party may require Accentia to assemble all or any part of the Collateral and make it available to Secured Party at any place and time designated by Secured Party; (iii) Secured Party may secure the appointment of a receiver of the Collateral
or any part thereof (to the extent and in the manner provided by applicable law); (iv) Secured Party may sell, resell, lease, use, assign, license, sublicense, transfer or otherwise dispose of any or all of the Collateral in its then condition or
following any commercially reasonable preparation or processing (utilizing in connection therewith any of Accentia’s assets, without charge or liability to Secured Party therefore) at public or private sale, by one or more contracts, in one or
more parcels, at the same or different times, for cash or credit, or for future delivery without assumption of any credit risk, all as Secured Party deems advisable; provided, however, that Accentia shall be credited with the net proceeds of
sale only when such proceeds are finally collected by Secured Party. Secured Party shall have the right upon any such public sale, and, to the extent permitted by law, upon any such private sale, to purchase the whole or any part of the Collateral
so sold, free of any right or equity of redemption, which right or equity of redemption Accentia hereby releases, to the extent permitted by law. McKesson shall give Accentia such notice of any private or public sales as may be required by the UCC
or other applicable law. 
  

 20 

 (b) For the purpose of enabling McKesson to exercise its rights and remedies under this Section 13 or
otherwise in connection with this Agreement, Accentia hereby, grants to Secured Party an irrevocable, non-exclusive and assignable license (exercisable without payment or royalty or other compensation to Accentia) to use, license or sublicense any
intellectual property Collateral, and including in such license reasonable access to all media in which any of the licensed items may be recorded or stored and to all computer software and programs used for the compilation or printout thereof and
sufficient rights of quality control in favor of Accentia to avoid the invalidation of any trademarks, service marks or trade names subject to the license. 
  
 (c) Secured Party shall not have any obligation to clean up, repair or improve or otherwise prepare the Collateral for sale. Secured Party has no
obligation to attempt to satisfy the Obligations by collecting them from any other Person liable for them, and Secured Party may release, modify or waive any Collateral provided by any other Person to secure any of the Obligations, all without
affecting Secured Party’s rights against Accentia. Accentia waives any right it may have to require Secured Party to pursue any third Person for any of the Obligations. Secured Party may comply with any applicable state or federal law
requirements in connection with a disposition of the Collateral and compliance will not be considered adversely to affect the commercial reasonableness of any sale of the Collateral. Secured Party may sell the Collateral without giving any
warranties as to the Collateral. Secured Party may specifically disclaim any warranties of title or the like. This procedure will riot be considered adversely to affect the commercial reasonableness of any sale of the Collateral; If Secured Party
sells any of the Collateral upon credit, Accentia will be credited only with payments actually made by the purchaser, received by Secured Party and applied to the indebtedness of the purchaser. In the event the purchaser fails to pay for the
Collateral; Secured Party may resell the Collateral and Accentia shall be credited with the proceeds of the sale. 
  
 (d) The cash proceeds actually received from the sale or other disposition or collection of Collateral (other than the proceeds of the sale of Accent Rx
or its assets), and any other amounts received in respect of the Collateral the application of which is not otherwise provided for herein, shall be applied first, to the payment of the reasonable costs and expenses of Secured Party in
exercising or enforcing its rights hereunder and hi collecting or attempting to collect any of the Collateral, and to the payment of all other amounts payable to Secured Party pursuant to Section 17 hereof; and second, to the payment of the
Obligations. Any surplus thereof which exists after payment and performance in full of the Obligations shall be promptly paid over to Accentia or otherwise disposed of in accordance with the UCC or other applicable law. Accentia shall remain liable
to Secured Party for any deficiency which exists after any sale or other disposition or collection of Collateral. 
  
 SECTION 14 Certain Waivers. Accentia waives, to the fullest extent permitted by law, (i) any right of redemption with respect to the Collateral,
whether before or after sale hereunder, and all rights, if any, of marshalling of the Collateral or other collateral or security for the Obligations; (ii) any right to require Secured Party (A) to proceed against any Person, (B) to exhaust any other
Collateral or security for any of the Obligations, (C) to pursue any remedy in Secured Party’s power, or (D) to make or give any presentments, demands for performance, notices of nonperformance, protests, notices of protests or notices of
dishonor in connection with any of the Collateral; and (iii) all claims, damages, and demands against Secured Party arising out of the repossession, retention, sale or application of the proceeds of any sale of the Collateral. 
  

 21 

 SECTION 15 Notices. All notices or other communications hereunder shall be in writing (including
by facsimile transmission or by email) and mailed, sent or delivered to the respective parties hereto at or to their respective addresses, facsimile numbers or email addresses set forth below their names on the signature pages hereof, or at or to
such other address, facsimile number or email address as shall be designated by any party in a written notice to the other parties hereto. All such notices and other communications shall be deemed to be delivered when a record (within the meaning of
the UCC) has been (i) delivered by hand; (ii) sent by mail upon the earlier of the date of receipt or five business days after deposit in the mail, first class (or air mail as to communications sent to or from the United States); (iii) sent by
facsimile transmission; or (iv) sent by email. 
  
 SECTION 16
No Waiver: Cumulative Remedies. No failure on the part of Secured Party to exercise, and no delay in exercising, any right, remedy, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of
any such right, remedy, power or privilege preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. The rights and remedies under this Agreement are cumulative and not exclusive of any rights,
remedies, powers and privileges that may otherwise be available to Secured Party. 
  
 SECTION 17 Costs and Expenses. 
  
 (a) Accentia agrees to pay on demand: 
  
 (i) all title, appraisal, survey, audit, consulting, search, recording, filing and similar costs, fees and expenses incurred or sustained by Secured Party in connection with this Agreement, any Document or the Collateral; and 
  
 (ii) all costs and expenses of Secured Party and the fees
and disbursements of counsel for which either APP or Accent Rx (or both) was obliged to reimburse Secured Party under the Documents, and for which Accentia is now obligated to reimburse Secured Party, and all costs and expenses of Secured Party, and
the fees and disbursements of counsel, in connection with the preparation and negotiation of this Agreement (and any amendments thereof), and any documents executed concurrently herewith (or amendments thereof) or in the future relating in any way
to the matters described in this Agreement, including the Recitals hereof, and in connection with the enforcement or attempted enforcement of, and preservation of any rights or interests under, this Agreement, the Credit Agreement, each other
Document (as they may be amended from time to time), including in any out-of-court workout or other refinancing or restructuring or in any bankruptcy case, and the protection, sale or collection of, of other realization upon, any of the Collateral,
including all expenses of taking, collecting, holding, sorting, handling, preparing for sale, selling, or the like, and all other expenses of sales and collections of Collateral. 
  
 (b) Any amounts payable to Secured Party under this Section 17 or otherwise under this Agreement if not paid upon demand
shall bear interest from the date of such demand until paid in full, at the Default Rate. 
  

 22 

 SECTION 18 Binding Effect This Agreement shall be binding upon, inure to the. benefit of and be
enforceable by Accentia, Secured Party and their respective successors and assigns and shall bind any Person who becomes bound as a debtor to this Agreement. Accentia may not assign, transfer, hypothecate or otherwise convey its rights, benefits,
obligations or duties hereunder without the prior express written consent of Secured Party. Any such purported assignment, transfer, hypothecation or other conveyance by Accentia without the prior express written consent of Secured Party shall be
void. Accentia acknowledges and agrees that in connection with an assignment of, or grant of a participation in, the Obligations, Secured Party may assign, or grant participations in, all or a portion of its rights and obligations hereunder. Upon
any assignment of Secured Party’s’ rights hereunder, such assignee shall have, to the extent of such assignment, all rights of Secured Party hereunder. Accentia agrees that, upon any such assignment, such assignee may enforce directly,
without joinder of Secured Party, the rights of Secured Party set forth in this Agreement. Any such assignee shall be entitled to enforce Secured Party’s rights and remedies under this Agreement to the same extent as if it were the original
secured party named herein. 
  
 SECTION 19 Governing Law.
This Agreement shall be governed by, and construed in accordance with, the law of the State of California, except as required by mandatory provisions of law and to the extent the validity or perfection of the security interests hereunder, or the
remedies hereunder, in respect of any Collateral are governed by the law of a jurisdiction other than California. 
  
 SECTION 20 Entire Agreement: Amendment. This Agreement contains the entire agreement of the parties with respect to the subject matter hereof and
shall not be amended except by the written agreement of the parties. 
  
 SECTION 21 Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under all applicable laws and regulations. If, however, any provision of this Agreement
shall be prohibited by or invalid under any such law or regulation in any jurisdiction, it shall, as to such jurisdiction, be deemed modified to conform to the minimum requirements of such law or regulation, or, if for any reason it is not deemed so
modified, it shall be ineffective and invalid only to the extent of such prohibition or invalidity without affecting the remaining provisions of this Agreement, or the validity or effectiveness of such provision in any other jurisdiction.

  
 SECTION 22 Counterparts. This Agreement may be executed
in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute but one and the same agreement. 
  
 SECTION 23 Termination. Upon payment and performance in full of all
Obligations, the security interest created under this Agreement shall terminate and Secured Party shall promptly execute and deliver to Accentia such documents and instruments reasonably requested by Accentia as shall be necessary to evidence
termination of all security interests given by Accentia to Secured Party hereunder; provided however that the obligations of Accentia under Section 17 hereof shall survive such termination. 
  

 23 

 SECTION 24 Conflicts. In the event of any conflict or inconsistency between this Agreement and the
Credit Agreement, the terms of this Agreement shall control. 
  
 SECTION 25 Right of McKesson to Convert Debt Into Equity. Until the first to occur of: (i) January 15, 2005, (ii) an IPO or establishment of public trading by Accentia or (iii) the sale of substantially all of Accentia’s assets
or the merger of Accentia with a publicly traded company (to which sale or merger McKesson has given its prior written consent which consent shall not be unreasonably withheld), McKesson may convert up to $3,900,000 in indebtedness owing by Accentia
to McKesson (or any affiliate of McKesson) into shares of Accentia Series E Convertible Preferred stock at the rate of $ 1.00 per share with Accentia’s consent. 
  
 SECTION 26 Conditions Subsequent. .It shall be an additional “Event of Default under this Agreement (and each of
the other documents executed concurrently herewith or pursuant hereto) should the following events (each a “Condition Subsequent”) fail to be and remain satisfied on or before January 31,2004: 
  
 (a) Account Control Agreements. McKesson shall have received an
Account Control Agreement in substantially the form of Exhibit D attached hereto for each and every deposit account of Accentia, Teamm Pharmaceuticals, Inc., and The Analytica Group, Inc. including those identified on Schedule 1.

  
 (b) Representation Certificate. McKesson shall have
received a fully and accurately completed Representation Certificate in the form of Exhibit H attached hereto, duly executed by each of Accentia, Teamm Pharmaceuticals, Inc., and The Analytica Group, Inc. 
  
 SECTION 27 Modification of Conditions to Release of Dr. Ryll From
Principal Guaranty. Section 2(d) of the Forbearance Agreement is hereby amended such that Dr. Ryll’s eligibility to be released from bis liability under the Principal Guaranty will be governed by the following: 
  
 Subject to the satisfaction of each of the conditions precedent set forth in
Section 3 of the Forbearance Agreement, McKesson agrees to undertake the following: . . . To release Dennis L. Ryll, M.D. from any further liability under that certain “Principal Guaranty” dated as of November 30, 1998 and executed by
Francis E. O’Donnell, Jr., M.D. and Dennis L. Ryll, M.D. in favor of McKesson effective on the date that is 91 days after June 28, 2004 provided that: 
  

	 	(i)	 	On or before December 31, 2003, McKesson has received all net proceeds from the sale of the assets of Accent Rx; 

  

	 	(ii)	 	On or before January 12, 2004, the Bridge Loan and all other sums payable to McKesson thereunder have been paid in full; 

  

	 	(iii)	 	all other payments to be made to McKesson on or before June 28, 2004, (including the reimbursement of fees, costs and expenses) that are referred to in the Forbearance Agreement or
which are referred to in the Assumption Agreement have been timely made; 

  

 24 

	 	(iv)	 	all conditions to the effectiveness of the Assumption Agreement have been and remain satisfied; and 

  

	 	(v)	 	no default or “Event of Default” has occurred under this Agreement or the Assumption Agreement through the date upon which the release of Dr. Ryll becomes effective,

  
 and provided further that at no time on
or before the date that is 91 days after June 28, 2004, none of Accent Rx, Accentia, HCG, HCG II, MOAB, RCT, BioVest, Francis E. O’Donnell, Jr., or Dennis L. Ryll, M.D. has become a debtor in a case under title 11 of the United States Code (the
“Bankruptcy Code”). 
  
 IN WITNESS WHEREOF, the parties
hereto have duly executed this Agreement, as of the date first above written. 
  

			
	 ACCENTIA, INC.

		
	 By
	 	 /s/ Francis E. O’Donnell

	 	 	 Title: Chairman & CEO

	
	 Accentia, Inc.

	 5310 Cypress Center Drive, Suite 101

	 Tampa, FL 33609

	 Attn: Francis E. O’Donnell, Jr., M.D.

	 Fax: 813-287-6642

	 email: FEOMDJR@aol.com

	
	 MCKESSON CORPORATION

		
	 By:
	 	 /s/ Ana Schrank

	 	 	 Ana Schrank

	 Title:
	 	 SVP Financial Services

	
	 McKesson Corporation

	 One Post Street

	 San Francisco, CA 94104

	 Attn: Ana Schrank

	 Fax; (415)983-9272

	 email: ana.schrank@mckesson.com

  

 30 

 FIRST AMENDMENT TO 
 ACCENTIA ASSUMPTION OF DEBT AND SECURITY AGREEMENT 
  
 THIS FIRST AMENDMENT TO ACCENTIA ASSUMPTION OF DEBT AND SECURITY AGREEMENT (this “Amendment”) is hereby executed as of this 9th day of February, 2005 by and between ACCENTIA BIOPHARMACEUTICALS, INC., a Florida corporation, formerly named Accentia, Inc.
(“Accentia”) and McKESSON CORPORATION, a Delaware corporation (“Secured Party” or “McKesson”), in order to amend that certain Accentia Assumption of Debt and Security Agreement dated as of December
31, 2003 (as modified or amended in writing, the “Assumption Agreement”), which was modified by (i) that certain letter agreement also dated as of December 31, 2003 and executed by and among Accentia, its affiliate Accent Rx, Inc.
(“Accent Rx”), and by McKesson (the “2003 Letter Agreement”), (ii) by the “Biologics Distribution Agreement” described below, and (iii) by a letter agreement dated as of October 6, 2004 and signed in favor
of McKesson by Accentia, Frances E. O’Donnell, Jr., M.D., Dennis L. Ryll, M.D., Regent Court Technologies, Hopkins Capital Group H, LLC, American Prescription Providers, Inc., American Prescription Providers of New York, Inc., and American
Prescription Providers of Pennsylvania, Inc. (the “Interlineation Letter”). This Amendment is being executed by the parties hereto based upon following facts and understandings: 
  
 RECITALS 
  
 A. Accentia is obligated to McKesson pursuant to the Assumption Agreement referred to above, pursuant to which (among other
things) Accentia assumed each and every debt, obligation, and liability owed by APP and/or Accent Rx to McKesson of every kind or nature, whether such debt, obligation, and liability was known, unknown, liquidated, unliquidated, disclosed, or
undisclosed, existing or contingent, and whether or not explicitly listed in the recitals to the Assumption Agreement or evidenced by a promissory note. The Assumption Agreement, and each document executed pursuant thereto or in connection therewith
(the “Assumption Documents”) remains in full force and effect, in accordance with its (or their) express written terms, subject to no defenses, off sets, or counterclaims whatsoever. Capitalized terms used in this Amendment not
otherwise defined herein will have the meanings they were defined to have in the Assumption Agreement. 
  
 B. As of January 31, 2005, the payment obligations owed to McKesson by Accentia relating to certain “Loans” assumed by Accentia (the
“Loan Debt”) aggregated $7,837,938.88, excluding attorneys’ fees and costs for which Accentia is obligated to reimburse McKesson. In addition, Accentia is from time to time obligated to pay certain sums to McKesson under the
Supply Agreement described in the Assumption Agreement and/or under a later executed supply agreement which superseded the Supply Agreement. As of January 31, 2005, there were no past due amounts owing to McKesson in connection with any supply
agreement. 
  
 C. Pursuant to the Assumption Agreement, Accentia
granted to McKesson, as security for the payment and performance of all “Obligations” (as that term was defined in the Assumption Agreement), a security interest in all of Accentia’s right, title and interest in, to and under
all of its personal property, wherever located and whether now existing or owned or hereafter acquired or arising, including all accounts, chattel paper, commercial tort claims, 

 
deposit accounts, documents, equipment (including all fixtures), general intangibles, intellectual property, patents, trademarks, service marks, trade names,
trade secrets, customer lists, copyrights, payment intangibles, instruments, inventory, investment property (including but not limited to all stock it holds in Teamm Pharmaceuticals, Inc., The Analytica Group, Inc. and BioVest Inc., called the
“Subsidiary Stock”), membership interests, letter-of-credit rights, money and all products, proceeds and supporting obligations of any and all of the foregoing. The security interests granted in Section 4 of the Assumption Agreement
were to be subject and junior to only those duly perfected security interests granted by Accentia to secure the “Senior Credit Facility,” which term was defined in the Assumption Agreement as: 
  
 that certain existing credit facility provided to Accentia by Harbinger
Mezzanine Partners, LP which presently aggregates $5,000,000 in principal outstanding, but which may be increased to equal as much as $13,000,000, for principal, in the future (but no more) and may be funded by a syndicate of lenders of which
Harbinger Mezzanine Partners, LP is a member, and shall also include any replacement facility provided by any lender or group of lenders, not affiliated with Accentia, which lender (or group of lenders) shall be satisfactory to McKesson and which
replacement facility shall be made on terms and conditions satisfactory to McKesson. 
  
 The Senior Credit Facility was and is solely the obligation Teamm Pharmaceuticals, Inc. and as of February 9, 2005, the total principal owing under the Senior Credit Facility equaled $5,000,000 for principal and all interest due and payable
thereon had been paid. Accentia has represented and warranted to McKesson that there are no outstanding defaults under the Senior Credit Facility. 
  
 D. Also pursuant to the Assumption Agreement: 
  
 1. Regent Court Technologies (a limited liability company of which Francis E. O’Donnell, Jr., M.D. is the managing member and which is referred to as
“RCT”) and Hopkins Capital Group II, LLC (a limited liability company of which Francis E. O’Donnell, Jr., M.D. is a manager and which is referred to as “HCG II”) executed a security agreement in favor of
McKesson for the purpose of securing all present and future obligations of Accentia owed to McKesson (including the Obligations) and all present and future obligations of RCT and/or HCG II to McKesson, which security agreement (the “New HCG
II/RCT Security Agreement”) encumbered (among other things) all the issued and outstanding shares of capital stock in BioDelivery Sciences International, Inc. and Star Scientific, Inc. owned by either RCT or HCG II, as more particularly
described in Schedule 1 to the New HCG II/RCT Security Agreement. 
  
 2. Hopkins Capital Group, LLC (a limited liability company of which Francis E. O’Donnell, Jr., M.D. is a manager and which is referred to as “HCG”) and MOAB Investments, LP (a limited partnership of which Dennis Ryll,
MD is an officer of the general partner and which is referred to as “MOAB”) executed a security agreement in favor of McKesson for the purpose of securing all present and future obligations of Accentia owed to McKesson (including
the Obligations) and all present and future obligations of HCG and/or MOAB owed to McKesson, which security agreement (the “New HCG/MOAB Security 

  

 2 

 
Agreement”) encumbered (among other things) all issued and outstanding shares of capital stock in Accentia Biopharmaceutieals, formerly known as
Accentia, Inc., owned by either HCG or MOAB (the “Accentia Stock”). 
  
 3. Each of Teamm Pharmaceuticals, Inc. (“Teamm”) and The Analytica Group, Inc. (“Analytica”), two wholly-owned subsidiaries of Accentia, executed in favor of McKesson (a) that certain
“Subsidiary Guaranty” (the “New Subsidiary Guaranty”) pursuant to which Teamm and Analytica jointly and severally guarantied the payment and performance by Accentia of all of Accentia’s obligations owed to McKesson,
and (b) that certain security agreement (the “New Subsidiary Security Agreement”) for the purpose of securing the payment and performance of the New Subsidiary Guaranty and all other obligations of Teamm and/or Analytica owed to
McKesson, which security agreement encumbered all personal property of Teamm and/or Analytica as set forth there in. 
  
 4. Each of Francis E. O’Donnell, Jr., M.D., Dennis L. Ryll, M.D., HCG II, RCT, American Prescription Providers, Inc., American Prescription Providers
of New York, Inc., and American Prescription Providers of Pennsylvania, Inc. executed a “Consent, Reaffirmation and Release Agreement” (the “Reaffirmation Agreement”), reaffirming their respective obligations under the
“Principal Guaranty” (a guaranty signed by Francis E. O’Donnell, Jr., M.D. and Dennis L. Ryll and more particularly described in the Assumption Agreement) and/or their third party pledge or security agreements and acknowledging that
the same remain in full force and effect with respect to the Obligations and notwithstanding the assumption by Accentia of the “APP Obligations” and the other obligations owed by Accent Rx to McKesson. 
  
 5. Accentia and McKesson entered into a “Warrant Purchase
Agreement” and Accentia issued a Warrant to McKesson granting McKesson a right to purchase up to 3,000,000 shares of Accentia’s Series E Convertible Preferred Stock, all as more particularly set forth in such agreements. In addition,
Accentia and McKesson entered into an “Investors’ Rights Agreement” dated as of “January , 2004” which remains in full force and effect. 
  
 E. On or about February 27, 2004, as an inducement to McKesson to enter into the Assumption Agreement, Accentia and McKesson
entered into that certain Biologics Distribution Agreement, granting to McKesson the exclusive right to distribute all current and future “Biologic Products” (as defined therein) developed or acquired by Accentia in the
“Territory” as defined in the Biologics Distribution Agreement. Pursuant to the Biologics Distribution Agreement, McKesson remitted to Accentia a non-interest bearing deposit of $3,000,000 which was to be refunded to McKesson upon
termination of the Biologics Distribution Agreement in accordance with Section 4 of that agreement. In addition, Accentia was obligated to (i) pay to McKesson a monthly fee equal to 5% of all “Net Revenue” as defined in the Biologics
Distribution Agreement, (ii) reimburse McKesson for all “Costs of Distribution” as defined in the Biologics Distribution Agreement, (iii) pay McKesson a termination payment of 5% of the net consideration received at any time by Accentia
from the sale, license or disposition of a Biologic Product for the Territory, and (iv) pay certain other sums if Accentia ceases to own 51% of the controlling interests in a subsidiary that owns a Biologics Product, all as more particularly
described in the Biologics Distribution Agreement. The Biologics Distribution Agreement specifically provided in Section 5 thereof that the term “Obligations” as defined in the Assumption Agreement would include that payment and
performance by Accentia of all its obligations under the Biologics Distribution Agreement. 
  

 3 

 F. Pursuant to the Assumption Documents, McKesson was to receive Account Control Agreements for all
deposit accounts of Accentia, Teamm, and Analytica. Accentia, Teamm, and Analytica have represented to McKesson that McKesson has received Account Control Agreements for all of their deposit accounts except for the deposit accounts listed on
Schedule 1 attached hereto (the “Uncontrolled Accounts”). 
  
 G. Accentia is also in default of its obligations under the Assumption Agreement with respect to the following “Payment Defaults”: (i) Accentia failed to pay off the Loans by September 1, 2004, and
(ii) Accentia has failed to make the monthly interest payments on the Loans in accordance with the Assumption Agreement. 
  
 H. Accentia is also in default for having changed its name from “Accentia, Inc.” to “Accentia Biopharmaceuticals, Inc.” without notice
to, or the consent of, McKesson. 
  
 I. Accentia has requested
that McKesson (a) forbear from exercising its creditors’ rights and remedies with regard to the failure of Accentia to deliver the account control agreements to McKesson relating to the Uncontrolled Accounts with respect to the Payment
Defaults, (b) agree to release its security interests in the Accentia Stock, (c) agree to subordinate its security interests in the assets of Accentia to a duly perfected security interest in favor of Missouri State Bank to secure new indebtedness
loaned by such financial institution having a principal amount not exceeding $5,000,000, and (d) restructure the outstanding debt owing to McKesson by Accentia in order to allow Accentia a means of consolidating its obligations to McKesson (the
“Restructuring Opportunity”). McKesson is willing to accommodate theses requests by Accentia to the extent explicitly set forth herein and otherwise subject to the terms and conditions of this Amendment. 
  
 NOW THEREFORE, for fair and valuable consideration, the receipt and adequacy of which are
hereby acknowledged, Accentia and McKesson hereby agree as follows: 
  
 SECTION 1 Definitions: Interpretation. 
  
 (a)
All capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings assigned to them in the Assumption Agreement. 
  
 (b) As used in this Amendment, the following terms shall have the following meanings: 
  
 “Contract Rate” means a rate of interest equal to ten percent (10%) per annum based on a 360-day year, for
actual days elapsed. 
  
 “Default Rate” means the
Contract Rate plus 5% per annum based on a 360-day year, for actual days elapsed. 
  
 “Full Payment Deadline” means the first to occur of (a) June 30, 2005, (b) the date Accentia or any of it subsidiaries consummates an initial public offering of its stock, (c) the date 

  

 4 

 
any creditor of Accentia, Teamm, Analytica, BioVest, or of any of the Guarantors asserts a default and/or begins exercising any of its creditors’ rights
and remedies with respect to any of such persons or entities or their asset, and (d) the date any of Accentia, Teamm, Analytica, BioVest, or of any of the Guarantors becomes a debtor in a case under title 11 of the United States Code (the
“Bankruptcy Code”). 
  
 “Guarantors”
means Francis E. O’Donnell, Jr., M.D., Dennis L. Ryll, M.D., HCG II, RCT, HCG, MOAB, American Prescription Providers, Inc., American Prescription Providers of New York, Inc., and American Prescription Providers of Pennsylvania, Inc. 

 
 (c) Where applicable and except as otherwise defined herein, terms used in
this Amendment shall have the meanings assigned to them in the UCC. 
  
 (d) In this Amendment, (i) the meaning of defined terms shall be equally applicable to both the singular and plural forms of the terms defined; and (ii) the captions and headings are for convenience of reference only and shall not affect
the construction of this Agreement. 
  
 SECTION 2 Confirmation
of Recitals, Etc. Accentia hereby acknowledges, agrees, represents and warrants to McKesson that each of the Recitals set forth at the outset of this Agreement is true and correct, and that each of the Assumption Agreement, the Assumption
Documents (including the Biologics Distribution Agreement) and all agreements and documents referred to in the Assumption Agreement, the earlier Forbearance Agreement and/or in the Credit Agreement that remained in place after the Assumption
Agreement was signed (collectively with the Assumption Documents as amended by this Amendment, now comprising the “Documents”), remain in full force and effect in accordance with their express written terms, except as any of the
same are or were explicitly modified or terminated by an agreement in writing signed by McKesson. Furthermore, Accentia has no known or unknown defenses, counterclaims, rights of offset or set off, recoupment, or any other causes of action against
McKesson or any Person that would prevent or interfere with the full collection and enforcement by McKesson of all such Documents. Accentia further acknowledges and agrees that there are no oral understandings between Accentia and McKesson and that
any purported agreement with McKesson must be in writing and signed by McKesson in order to be enforceable against McKesson. 
  
 SECTION 3 Agreements by McKesson. Subject to the satisfaction of the conditions precedent set forth in Section 4 below, McKesson agrees as follows
as an amendment to the Assumption Agreement: 
  
 (a) Waiver of
Certain Defaults. Effective upon the satisfaction of the conditions precedent set forth in Section 4 below, McKesson agrees to waive the following defaults and only the following defaults: 
  
 i. The default that occurred for failure to deliver Account
Control Agreements with regard to the Uncontrolled Accounts, provided that each entity which is the owner of one of the Uncontrolled Accounts shall deliver by the 10th calendar day of each calendar month a copy of the bank statement for the prior
calendar month ending for each of the Uncontrolled Accounts indicated the activity in such accounts and the ending balances of such accounts. 
  

 5 

 ii. Each of the Payment Defaults defined above that occurred prior to February 9, 2005.

  
 iii. Each non-Payment Default that occurred
prior to February 9, 2005. 
  
 (b) Subordination to Lien of
Missouri State Bank. Effective upon the satisfaction of the conditions precedent set forth in Section 4 below, McKesson agrees to subordinate the priority of its liens and security interests in the personal property of Accentia to a duly
perfected security interest in favor of Missouri State Bank which secures a loan to Accentia not to exceed $5,000,000 for principal. Said subordination shall be of priority only and (i) payments to McKesson as required by the Assumption Documents,
as amended by this Amendment, shall be permitted to continue, and (ii) McKesson shall not be obligated to agree to any restrictions on its ability to exercise its rights and remedies as it may in its discretion determine, so long as McKesson acts in
accordance with the Assumption Documents and applicable law. The foregoing subordination shall be in addition to its subordination to the Senior Credit Facility. 
  
 (c) Release of Lien in Accentia Stock. Effective upon the satisfaction of the conditions precedent set forth in
Section 4 below, McKesson shall release its lien on the Accentia Stock owned by HCG and MOAB provided that McKesson may retain possession of the Accentia Stock, and provided further that unless and until all sums owing to McKesson by
any of Accentia, HCG or MOAB are paid in full, (i) each of HCG and MOAB agrees not to sell, convey, hypothecate, encumber, pledge or otherwise transfer or dispose of any interest in the Accentia Stock to a third party without the consent of
McKesson, and (ii) each of Frances E. O’Donnell, Jr., M.D. and Dennis L. Ryll, M.D. agrees not to sell, convey, hypothecate, encumber, pledge or otherwise transfer or dispose of any interest in HCG or MOAB (or the Accentia Stock) to a third
party without the consent of McKesson. 
  
 (d) Termination of
Right to Convert the Loan Debt into Series E Convertible Preferred Stock. Effective upon the satisfaction of the conditions precedent set forth in Section 4 below, McKesson agrees to waive any and all right to convert any portion of the Loan
Debt into shares of Capital Stock, including shares of Series E Convertible Preferred Stock of Accentia. 
  
 (e) Agreement Not To Exercise Warrant to Purchase Shares of Series E Convertible Preferred Stock. Effective upon the satisfaction of the conditions
precedent set forth in Section 4 below, McKesson agrees to waive its right to purchase up to 3,000,000 shares of Series E Convertible Preferred Stock pursuant to the Warrant Purchase Agreement and or the Warrant granted to McKesson by Accentia.

  
 SECTION 4 Conditions Precedent to Bank Obligations. It
shall be a condition precedent to the enforceability of each and every obligation of McKesson hereunder, that each and all of the following shall be and remain satisfied: 
  
 (a) This Agreement. McKesson shall have received an original counterpart of this Amendment, duly executed by
Accentia. 
  

 6 

 (b) Reaffirmation by Guarantors and Third Party Pledgors. Each of Francis E. O’Donnell, Jr.,
M.D., Dennis L. Ryll, M.D., HCG II, RCT, HCG, MOAB and the other signatories thereto (collectively, the “Guarantors”) shall have executed the “Consent to Amendment, Reaffirmation and Release Agreement” in the form of
Exhibit C attached hereto (the “Consent to Amendment Agreement”), reaffirming their respective obligations under the Principal Guaranty and/or their third party pledge or security agreements and acknowledging that the same
remain in full force and effect notwithstanding this Amendment and any other events which may have occurred since and of such agreements were executed in favor of McKesson. 
  
 (c) Payments. McKesson shall have received a payment in good funds of not less than $1,900,000 which shall be used by
McKesson to pay the following in the order indicated: 
  
 i. first, to pay all attorneys’ fees and costs incurred by or on behalf of McKesson in connection with this Amendment, the Assumption Agreement, the Obligations, or for which Accentia or any of the Guarantors must otherwise reimburse
McKesson under the Documents; 
  
 ii. next, to
pay all accrued and unpaid interest relating to the Loan Debt as has accrued through the date of payment; 
  
 iii. last, to the principal portion of the Loan Debt. The principal owing after application of the $1,900,000 as indicated in this Section
4(c) shall defined as the “Remaining Principal” 
  
 (d) Trade Debt. Each of Accentia, Teamm, Analytica or BioVest shall be current on their trade debt obligations owing to McKesson whether under the Supply Agreement or otherwise; and 
  
 (e) No Default. No Event of Default (or event which with the giving of
notice or the passage of time, or both would constitute an Event of Default) shall have occurred, other than those that are to be waived under this Amendment. 
  

(f) UCC Amendments. McKesson shall have filed amendments of its UCC financing statements to reflect the name change of Accentia from
“Accentia, Inc.” to “Accentia Biopharmaceuticals, Inc.” and McKesson shall be satisfied that there have been no intervening liens filed since the name change which would impact McKesson’s relative lien priority
vis-à-vis creditors to which McKesson agreed to subordinate its lien position. 
  
 SECTION 5 Payment of Remaining Debt 
  
 (a) Interest. From and after the date of payment of the sums required to be paid pursuant to Section 4(c) above, interest shall accrue on the Remaining Principal (and on any other sums which are subject to the
accrual of interest as provided in the Assumption Agreement or in the Biologics Distribution Agreement) at the Contract Rate, subject to potential increase to the Default Rate immediately and automatically upon the occurrence of an Event of Default.
In other words, no prior notice of the interest rate increase need be given before the Default Rate goes into effect. 
  

 7 

 (b) Payoff. Unless Accentia takes advantage of the Restructure Opportunity described in Section 9
below, all Obligations that remain outstanding after the sums payable pursuant to Section 4(c) above are paid, including the Deferred Obligations, plus accrued and unpaid interest as provided herein, together with any fees, costs and expenses
incurred by McKesson in connection with the Obligations, plus any other indebtedness owed by Accentia to McKesson (or to any affiliate of McKesson), other than in connection with the Biologics Distribution Agreement, shall be paid in full on or
before the “Full Payment Deadline” defined above (unless and to the extent McKesson converts any portion of the Obligations to equity, which McKesson may elect to do in its sole and absolute discretion on terms no less favorable than the
proposed Series E financing that Accentia expected to obtain in 2003, all as more particularly set forth in Section 25 of the Assumption Agreement). The payment obligations under the Biologics Distribution Agreement shall be paid as and when
provided in the Biologics Distribution Agreements, subject to acceleration upon the occurrence of a default thereunder or an Event of Default under the Assumption Agreement (as amended from time to time in writing and signed by McKesson).

  
 (c) In the absence of acceleration after an Event of Default,
accrued interest shall be payable to McKesson (or the applicable affiliate, if any) monthly in arrears on the first business day of each calendar month for the previous month ending commencing with March 1, 2005. 
  
 (d) In no event shall the interest rate or rates payable under the Assumption
Agreement as amended by this Amendment or in connection with any of the Obligations including the Assumed Indebtedness, plus any other amounts paid in connection herewith, exceed the highest rate permissible under any law that a court of competent
jurisdiction shall, in a final determination, deem applicable. Accentia and McKesson, in executing this Amendment and each of the other Documents, intend legally to agree upon the rate or rates of interest and manner of payment stated within it;
provided, however, that, anything contained herein or in any Loan Document to the contrary notwithstanding, if said rate or rates of interest or manner of payment exceeds the maximum allowable under applicable law, then, ipso facto as of the date of
this Amendment and/or such other Loan Document, Accentia is and shall be liable only for the payment of such maximum as allowed by law, and payment received from Accentia in excess of such legal maximum, whenever received, shall be applied to reduce
the principal balance of the Obligations to the extent of such excess. 
  
 SECTION 6 Representations and Warranties. Accentia represents and warrants to McKesson that: 
  
 (a) Accentia is a corporation duly organized, validly existing and in good standing under the laws of the state of Florida and has all requisite power and
authority to execute, deliver and perform its obligations under this Amendment and that its full, legal name is Accentia Biopharmaceuticals, Inc. although it uses the “dba” of “Accentia Specialty Pharmacy,” which is not a
separate legal entity distinct from Accentia. 
  
 (b) The
execution, delivery and performance by Accentia of this Amendment have been duly authorized by all necessary action of Accentia and its Board of Directors, and this Amendment constitutes the legal, valid and binding obligation of Accentia,
enforceable against Accentia in accordance with its terms. 
  

 8 

 (c) No authorization, consent, approval, license, exemption of, or filing or registration with, any
governmental authority or agency, or approval or consent of any other Person, is required for the due execution, delivery or performance by Accentia of this Amendment. 
  
 (d) Accentia’s chief executive office and principal place of business (as of the date of this Amendment) is located at
the address set forth in Schedule 1 to the Assumption Agreement; Accentia’s exact legal name is currently as set forth in the first paragraph of this Agreement; and all other locations where Accentia conducts business or Collateral is
kept (as of the date of this Amendment) are set forth in Schedule 1 to the Assumption Agreement. 
  
 (e) Schedule 1 to the Assumption Agreement also accurately sets forth the current proper names (as reflected in their official formation or
registration documentation as filed with the appropriate office of their jurisdictions of organization), jurisdictions of organization, and chief executive offices of each of HCG, HCG II, RCT, Accent Rx, BioVest, Teamm, and Analytica. 
  
 (f) No control agreements exist with respect to any Collateral other than
control agreements in favor of Secured Party. 
  
 (g) Accentia
does not have or hold any chattel paper, letter-of-credit tights or commercial tort claims except as disclosed to Secured Party. 
  
 (h) The names and addresses of all financial institutions and other Persons at which Accentia, Accent Rx, Teamm Pharmaceuticals, Inc., and/or The
Analytica Group, Inc. currently maintains a deposit and securities accounts, and the account numbers and account names of such accounts, are set forth in Schedule 1 to the Assumption Agreement. 
  
 SECTION 7 Covenants, Etc. So long as any of the Obligations remain
unsatisfied, Accentia agrees that the Covenants set forth in the Assumption Agreement remain binding upon Accentia. 
  
 SECTION 8 Release. In further consideration of McKesson’s willingness to enter into the Amendment, and as a material inducement to McKesson to
do so, Accentia hereby forever releases and discharges McKesson and its predecessors-in-interest, and their respective officers, directors, shareholders, employees, agents, attorneys, advisors, and successors-in-interest from any and all claims,
demands, controversies, actions, causes of action, obligations, liabilities, expenses, costs, attorneys’ fees and damages of any nature or character, or any kind, at law or in equity, past, present, or future, known or unknown, suspected or
unsuspected, flow owned or hereafter acquired, arising out of or relating in any way to APP, Accent Rx, Accentia, the Assumed Indebtedness, any of the Assumed Accent Rx Debt Documents, the Supply Agreement, the Documents (as each of such terms is
defined in the Assumption Agreement), the Obligations, any of the Guarantors (as that term is defined in the Amendment) or any other matter whatsoever, save and except only McKesson’s obligations to be performed after the date hereof under the
Assumption Agreement as amended by this Amendment. It is the intention of 

  

 9 

 
Accentia that the foregoing release shall be effective as a bar to all actions, fees, damages, losses, claims, liabilities, demands or debts whatsoever, of
any kind or nature, known or unknown, suspected or unsuspected. Accentia expressly waives any and all rights and benefits conferred upon it by virtue of California Code of Civil Procedure section 1542 (or any similar law) which provides as follows:

  
 A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE
CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR. 
  
 Accentia expressly acknowledges that McKesson has separately bargained for the foregoing waiver of the provisions of California Code of
Civil Procedure section 1542 and has been advised by its own counsel of the full legal consequences of this release and waiver. 
  
 SECTION 9 Restructure Opportunity. After the satisfaction of the conditions precedent set forth in Section 4 above, including the payment of not
less than $1,900,000 to McKesson, Accentia shall have the opportunity tip to and including March 31, 2005 to provide McKesson with written notice of its desire in its discretion to take advantage of the “Restructure Opportunity” designed
by Accentia to enable Accentia to consolidate its obligations owing to McKesson and to obtain certain benefits identified by Accentia. The Restructure Opportunity allows Accentia to (I) liquidate all payment obligations owing to McKesson (other than
with respect to trade debt under a supply agreement or otherwise), (II) terminate the Biologics Distribution Agreement and related refundable deposit, and (III) repurchase Accentia’s equity, consisting of 4,289,000 shares of Series E Preferred
stock (or equivalent conversion value in common shares if converted) by paying the sum of $14,200,000.00 as follows: (i) cash at closing of the Restructure Opportunity in the amount $4,200,000.00 plus all accrued and unpaid interest from the date of
this Amendment through the date of the “Restructure Closing” defined below (the “Cash Payment”), and (ii) a promissory note (the “Restructure Note”) in the original principal amount of $10,000,000, the
terms of which are more particularly described below, in each case in lieu of the payment terms otherwise set forth in the Assumption Agreement (as modified by this Amendment) and in the Biologics Distribution Agreement. The means of utilizing the
Restructure Opportunity shall be as expressly stated in this Section 9. 
  
 (a) Conditions to Use of Restructure Opportunity. If Accentia desires to utilize the Restructure Opportunity, there must be no default or defined Event of Default under the Assumption Agreement or the other Assumption Documents, and
on or before close of business San Francisco, California time on March 31, 2005, McKesson must receive (i) written notice of Accentia’s intent to utilize the Restructure Opportunity, (ii) the Cash Payment in good funds, (iii) the Restructure
Note described below, (iv) acknowledgment from the Guarantors that their guaranties and any third party security agreements remain in place and in full force and effect with regard to the sums owing under the Restructure Note inasmuch as it is the
identical debt as what is already guarantied or secured by such guaranties and/or third party security agreements, and (v) a general release of claims signed by Accentia and each of the Guarantors. 

  

 10 

 
The date when all these items are received shall be defined herein as the “Restructure Closing,” so long as this occurs on or before the
first to occur of March 31, 2005 (the “Restructure Deadline”), and the date that a default or defined Event of Default occurs under the Assumption Agreement (as amended from time to time), the Biologics Distribution Agreement or any
Assumption Document. 
  
 (b) Restructure Note. The
“Restructure Note” shall be a promissory note in the original principal amount of$ 10,000,000 and payable to the order of McKesson by Accentia. The principal owing under the Restructure Note shall bear interest at the Contract Rate unless
and until an Event of Default occurs, in which case interest shall accrue and be payable at the Default Rate. All sums owing under the Restructure Note shall be due and payable on the first to occur of (i) the date that is 90 calendar days after the
Restructure Closing, (ii) the date that is five (5) calendar days after the date upon which Accentia completes an initial public offering of its securities, and (iii) the date upon which an Event of Default under the Assumption Agreement or the
other Assumption Documents occurs. The Restructure Note shall provide that Accentia shall remain obliged to reimburse McKesson for all fees, costs and expenses incurred by McKesson in connection with Accentia, the Restructure Note, the collateral
therefor, the Assumption Agreement, and any of the Guarantors or pledgors of collateral, which sums shall be payable upon demand or in any event at the time of maturity of the Restructure Note, whether by acceleration or otherwise. The Restructure
Note shall otherwise have terms satisfactory to McKesson. 
  
 (c)
Extension of Restructure Deadline. Accentia shall be permitted to extend the March 31, 2005 “Restructure Deadline” for up to 60 days if (i) no Event of Default has occurred or is continuing, (ii) on or before March 31, 2005 Accentia
delivers to McKesson notice of its desire for an extension of the Restructure Deadline along with a payment, in good funds, of a fee (the “Extension Fee”) equal to $100,000, which Extension Fee shall be paid to McKesson as a fee and
shall not be applied to the indebtedness of Accentia owing to McKesson. 
  
 (d) Cancellation of other Obligations. In the event Accentia duly and timely invokes the Restructure Opportunity, including by making the Cash Payment and delivering the Restructure Note in full compliance with the Section 9, then
Accentia shall have no further obligation to McKesson under the Biologics Distribution Agreement (other than with respect to any confidentiality provisions, if any), and in particular shall no longer have any obligation to repay the $3,000,000
refundable deposit made by McKesson under the Biologics Distribution Agreement, because all such payment obligations (to the extent unpaid) shall have been incorporated into the sums owing under the Restructure Note. 
  
 (e) Collateral. All collateral for (and guaranties) of the Loan Debt
and any other Obligations owing to McKesson shall remain as security for (or guaranties of) the Restructure Note, subject to any existing written subordination agreements signed by McKesson. 
  
 (f) Deliveries at Restructure Closing. At the Restructure Closing,
Accentia shall deliver to McKesson: (a) $4,200,000 in Cash and (b) duly executed Restructure Note in form satisfactory to McKesson and its legal counsel. At the Restructure Closing, upon receipt of delivery of the items to be delivered by Accentia
to McKesson as set forth in the prior sentence, McKesson shall deliver to Accentia: (a) original stock certificates to 4,289,000 shares of Series E 

  

 11 

 
Convertible Preferred Stock (or any Accentia Common Stock issued upon conversion of the Accentia Series E Convertible Preferred stock) held of record by
McKesson together with duly executed assignments to Accentia and an assignment of any accrued but unpaid dividends on said shares of Series E Preferred stock; and (b) duly executed written termination of the Biologics Distribution Agreement,
including a written waiver of all of McKesson’s rights in and to the non-interest bearing deposit of $3,000,000 paid by McKesson under the Biologics Distribution Agreement, each in form satisfactory to Accentia and its legal counsel.

  
 SECTION 10 Miscellaneous. 
  
 (a) Governing Law. This Amendment shall be governed by, and construed
in accordance with, the law of the State of California. 
  
 (b)
Entire Agreement: Amendment. This Amendment contains the entire agreement of the parties with respect to the subject matter hereof and the Assumption Agreement and other documents shall not be further amended except by the written agreement
of the parties. 
  
 (c) Acknowledgement. In granting
Accentia (and the Guarantors) the accommodations set forth in this Amendment, McKesson is not establishing (and has not established) a pattern and practice or course of dealing of (i) granting extensions of payment due dates or making accommodations
to Accentia or any Guarantor to address the consequences of Events of Default, (ii) amending the Assumption Agreement or any of the Assumption Documents to accommodate Accentia or any Guarantor in any way, nor (iii) forbearing or refraining from
exercising each and all of McKesson’s rights and remedies under the Assumption Documents, the Documents and applicable law upon the occurrence of any Event of Default. Except as expressly amended in this Amendment or in another writing signed
by McKesson, each and all of the Assumption Documents and the Documents remains in full force and effect in accordance with its express written terms. 
  
 (d) Time. Time is of the essence of each term of the Assumption Documents, including this Amendment. 
  
 (e) Third Party Beneficiaries. There are no third party beneficiaries
of this Amendment nor of any of the Assumption Documents (or the Documents). 
  
 (f) Counterparts. This Amendment may be executed in any number of counterpart and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all
of which taken together shall constitute but one and the same agreement. 
  

 12 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as of the date first above
written. 
  

			
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	By:	 	 /s/ Alan Pearce

	Title:	 	Chief Financial Officer
	
	Accentia Biopharmaceuticals, Inc.
	5310 Cypress Center Drive, Suite 101
	Tampa, FL 33609
	Attn:	 	Alan Pearce
	Fax:	 	813-287-6642
	email:	 	alan.pearce@comcast.net
	
	MCKESSON CORPORATION
		
	By:	 	 Ana Schrank

	 	 	Ana Schrank
	Title:	 	VP Financial Services
	
	McKesson Corporation
	One Post Street
	San Francisco, CA 94104
	Attn.:	 	Ms. Ann Schrank
	Fax:	 	(415) 732-2967
	email:	 	ana.schrank@mckesson.com

  

 13 

 Schedule 1 
  

Uncontrolled Accounts 
  
 1. Accentia Biopharmaceuticals, Inc. Accounts 
 (including for
any “dba” of Accentia) 
  

	 	a.	 	For Accentia maintained at Missouri State Bank: 

  
 Acct. No. 8801714 
  
 Acct. No. 8802365 
  

	 	b.	 	For Accentia Specialty Pharmacy maintained at Missouri State Bank: 

  
 Acct. No. 8802332 
  
 Acct. No. 8802357 
  
 Acct. No. 8802340 
  
 2. The Analytica Group Accounts 
  
 Acct. No. 8802373 maintained at Missouri State Bank 
  
 3. Teamm Pharmaceuticals, Inc. Accounts 
  
 Acct. No. 8802399 maintained at Missouri State Bank 
  
 Acct. No. 8171229130 maintained at First Citizens Bank 
  
 4. Accent Rx Accounts 
  
 Acct. No. 323-196357 maintained at JP Morgan Chase 
  

 14 

 EXHIBIT A 
  

Consent to Amendment, Reaffirmation and Release Agreement 
  
 This “Consent to Amendment, Reaffirmation and Release Agreement” is hereby executed by the undersigned parties as
of this      day of February, 2005 as a condition to the obligations of McKesson Corporation (“McKesson”) under that certain “First Amendment to Accentia Assumption of Debt and Security
Agreement” dated as of the date hereof (the “Amendment”) and executed by and between McKesson and Accentia Biopharmaceuticals, Inc., formerly known as Accentia, Inc. (“Accentia”). Each of the undersigned persons and
entities, as a material inducement to McKesson to enter into the Amendment hereby confirms, acknowledges and agrees in favor of McKesson that: 
  
 (a) it or he has read the Amendment and consents to its terms, including without limitation the subordination by McKesson of its security interest in the
assets of Accentia to liens in favor of Missouri State Bank; 
  
 (b) it or he acknowledges and agrees that each of the Recitals set forth in the Amendment (and those set forth in the Assumption Agreement and/or in the Forbearance Agreement) is true and correct and binding upon such undersigned person or
entity; 
  
 (c) each guaranty, third party pledge agreement,
security agreement or other agreement signed by any of the undersigned persons or entities in favor of McKesson or any affiliate of McKesson (as such documents may have been amended in writing from time to time) remains in full force and effect and
each is enforceable in accordance with its express written terms, except that all references in any such guaranty or other agreement to any debt or obligation of APP or Accent Rx or “Borrower” shall be deemed to refer to any debt or
obligation of Accentia, whether or not assumed from APP or Accent Rx, and whether or not now existing or hereafter arising; 
  
 (d) in the event that Accentia shall determine to invoke the Restructure Opportunity described in Section 9 of the Amendment, (i) each of the persons and
entities has given its consent to such restructure and no further consent shall be required, and (ii) each guaranty, third party pledge agreement, security agreement or other agreement signed by any of the undersigned persons or entities in favor of
McKesson or any affiliate of McKesson (as such documents may have been amended in writing from time to time) shall remain in full force and effect with regard to the remaining indebtedness owing to McKesson or any affiliate of McKesson, including
under the Restructure Note; and 
  
 (e) none of the undersigned
persons or entities has any known or unknown defenses, counterclaims, rights of offset, set off, or recoupment, or any other causes of action against McKesson or any person or entity that would prevent or interfere with the full collection and
enforcement by McKesson of their respective obligations to McKesson, including but not limited to any guaranty, third party pledge agreement, or security agreement signed by any or each of them in favor of McKesson, where references to
“Borrower” (or other names for APP) and/or to Accent Rx (if any) are deemed to refer to Accentia. 
  

 15 

 In addition to the foregoing, by executing where indicated below, (i) each of HCG and MOAB agree not to
sell, convey, hypothecate, encumber, pledge or otherwise transfer or dispose of any interest in the Accentia Stock to a third party without the consent of McKesson, and (ii) each of Frances E. O’Donnell, Jr., M.D. and Dennis L. Ryll, M.D. agree
not to sell, convey, hypothecate, encumber, pledge or otherwise transfer or dispose of any interest in HCG or MOAB (or the Accentia Stock) to a third party without the consent of McKesson. 
  
 In further consideration of McKesson’s willingness to enter into the
Amendment, and as a material inducement to McKesson to do so, each of the undersigned persons or entities (collectively, the “Releasing Parties”) hereby forever releases and discharges McKesson and its predecessors- in-interest, and their
respective officers, directors, shareholders, employees, agents, attorneys, advisors, and successors-in-interest (the “Released Parties”) from any and all claims, demands, controversies, actions, causes of action, obligations, liabilities,
expenses, costs, attorneys’ fees and damages of any nature or character, or any kind, at law or in equity, past, present, or future, known or unknown, suspected or unsuspected, now owned or hereafter acquired, arising out of or relating in any
way to APP, Accent Rx, Accentia, the Assumed Indebtedness, any of the Assumed Accent Rx Debt Documents, the Supply Agreement, the Documents (as each of such terms is defined in the Assumption Agreement), the Obligations, any of the Guarantors (as
that term is defined in the Amendment) or any other matter whatsoever, save and except only McKesson’s obligations to be performed after the date hereof under the Assumption Agreement as amended by the Amendment. 
  
 It is the intention of each of the undersigned persons and entities that the
foregoing release shall be effective as a bar to all actions, fees, damages, losses, claims, liabilities, demands or debts whatsoever, of any kind or nature, known or unknown, suspected or unsuspected. Each of the undersigned persons or entitles
expressly waives any arid all rights and benefits conferred upon him or it by virtue of California Code of Civil Procedure section 1542 (or any similar law) which provides as follows: 
  
 A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME
OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR. 
  
 Each of the undersigned persons or entities expressly acknowledges that McKesson has separately bargained for the foregoing waiver of the provisions of
California Code of Civil Procedure section 1542 and each has been advised by his or its own counsel of the full legal consequences of this release and waiver. 
  

			
	AMERICAN PRESCRIPTION PROVIDERS, INC.
		
	By:	 	Exhibit
	Its:	 	  

  
 [Signatures
continued on next page.] 
  

 16 

			
	AMERICAN PRESCRIPTION PROVIDERS OF
NEW YORK, INC.
		
	By:	 	Exhibit
	Its:	 	  

	
	AMERICAN PRESCRIPTION PROVIDERS OF PENNSYLVANIA, INC.
		
	By:	 	Exhibit
	Its:	 	  

	
	Exhibit
	FRANCIS E. O’DONNELL, JR., M.D.
	
	Exhibit
	DENNIS L. RYLL, M.D.
	
	REGENT COURT TECHNOLOGIES
		
	By:	 	Exhibit
	 	 	Francis E. O’Donnell, Jr., M.D.
	 	 	Managing Member
	
	HOPKINS CAPITAL GROUP II, LLC
		
	By:	 	Exhibit
	 	 	Francis E. O’Donnell, Jr., M.D.
	 	 	Managing Member
	
	HOPKINS CAPITAL GROUP, LLC
		
	By:	 	Exhibit
	 	 	Francis E. O’Donnell, Jr., M.D.
	 	 	Managing Member
	
	HOPKINS CAPITAL GROUP, LLC
		
	By:	 	Exhibit
	Title:	 	Managing Member
	
	709 The Hamptons Lane
	Town and Country, Mo. 63017
	Attn:	 	Frank E. O’Donnell, Jr.
	Fax:	 	(314) 434-7030

  
 [Signatures
continued on next page.] 
  

 17 

					
	MOAB INVESTMENTS, LP
		
	By:	 	Exhibit
		
	By:	 	  

	Title:	 	Managing Member
		
	Address	 	  

	 	 	 	 	  

	 	 	 	 	  

  

 18 

					
	 McKesson Corporation
 One Post Street
 San Francisco, CA 94104
 Tel. 415-983-7153
 Fax 415-732-2967
  
 Ana Schrank
 Vice President, Financial Services
	 	 	 	

  
  
 May 31, 2005 
  
 FIRST CLASS MAIL AND E-MAIL 
  
 Accentia
Biopharmaceuticals, Inc. 
 324 South Hyde Park Ave., Suite 350 
 Tampa, FL 33606 
 Attn: Francis E. O’Donnell, Jr. M.D. 
  

	Re:	 	Modification of “First Amendment to Accentia Assumption of Debt and Security Agreement” dated as of February 9, 2005 (the “First Amendment”) Executed by Accentia
Biopharmaceuticals, Inc. (“Accentia”) and McKesson Corporation (“McKesson”). 

  

Gentlemen: 
  
 You have requested that McKesson agree to extend the deadline by which Accentia must act to satisfy the conditions necessary to take advantage of the “Restructure Opportunity” described in Section 9 of the
First Amendment, which deadline presently would expire as of the date of this letter absent the willingness of McKesson to provide Accentia with an extension of the deadline. Subject to the satisfaction of the conditions set forth below, McKesson
agrees that the deadline by which the conditions set forth in Section 9 of the First Amendment must be satisfied in order for Accentia to avail itself of the Restructure Opportunity described therein shall be extended from May 31, 2005 until close
of business California time on June 30, 2005. 
  
 It shall be a
condition to the extension provided above that Accentia, and each of the “Guarantors” (defined below) of the obligations owed to McKesson by Accentia, shall duly execute an original counterpart of this letter (the “Restructure
Opportunity Extension Letter”) where indicated below and deliver it to McKesson. The “Guarantors” are defined herein as including each of the Guarantors as that term is used in the First Amendment and in the documents executed
concurrently therewith, and includes Francis E. O’Donnell, Jr., M.D., Dennis L. Ryll, M.D., Regent Court Technologies, Hopkins Capital Group, LLC, Hopkins Capital Group II, LLC, and MOAB Investments, LP. The term “Guarantors” no
longer includes American Prescription Providers, Inc. (“APP”), American Prescription Providers of New York, Inc., American Prescription Providers of Pennsylvania, Inc., American Prescription Providers of Florida, Inc., nor American
Prescription Providers of Georgia, Inc. based on the representations 

 MOAB Investments, LP 
  
 May 31, 2005 
  
 and warranties to McKesson made by Accentia and each of the undersigned Guarantors (which representations and warranties are hereby confirmed by each of them) that: 
  
 (i) APP was dissolved on December 30, 2002; 
  
 (ii) each of American Prescription Providers of New York, Inc., American
Prescription Providers of Pennsylvania, Inc., American Prescription Providers of Florida, Inc., and American Prescription Providers of Georgia, Inc. transferred all of their respective assets (if any) either to Accent Rx, Inc. (“Accent
Rx”) or to APP, which then transferred those assets to Accent Rx, such that Accent Rx came to hold all such assets before transferring them to Accentia at or before the time Accent Rx assumed all of the indebtedness owing by APP to McKesson;

  
 (iii) American Prescription Providers of New York, Inc. has
been dissolved; 
  
 (iv) American Prescription Providers of
Pennsylvania, Inc. has not yet dissolved, but has ceased operations, and is likely to dissolve or be dissolved in the near term; 
  
 (v) American Prescription Providers of Florida, Inc. has been administratively dissolved and wound up its affairs; and 
  
 (vi) American Prescription Providers of Georgia, Inc. is no longer in good
standing, and has been dissolved. 
  
 Upon so executing where
indicated below, Accentia and each of the Guarantors, respectively, shall immediately and subject to no conditions precedent thereby acknowledge and agree as follows: 
  
 a. That as of the date hereof, that certain “Accentia Assumption of Debt and Security Agreement” dated as of
December 31, 2003 (as modified or amended in writing, from time to time, including by the First Amendment, called the “Assumption Agreement”), remains in full force and effect in accordance with its express written terms, and each and any
document or agreement executed by Accentia or any Guarantor in favor of or for the benefit of McKesson remains in full force and effect (except as expressly modified or released in a writing signed by McKesson) subject to no defenses, counterclaims
or offsets whatsoever, whether known or unknown, and whether legal or equitable in nature; 
  
 b. That each Guarantor hereby consents to the grant of the extension of the deadline for Accentia to take advantage of the “Restructure Opportunity” described in Section 9 of the First Amendment described
above and agrees that such extension shall not give rise to any defense, counter claim or offset against any obligation that any Guarantor owes to McKesson under any document executed by such Guarantor in favor of McKesson or under applicable law;

  

 2 

 MOAB Investments, LP 
  
 May 31, 2005 
  
 c. McKesson had no and has no obligation to provide the extension set forth in this Restructure Opportunity Extension Letter and in granting the extension, McKesson is not establishing a pattern and practice or course
of dealing of providing such extensions in the future, nor of modifying the Assumption Agreement in any manner whatsoever; and 
  
 d. Except as expressly modified in a writing signed by McKesson, the Assumption Agreement remains in full force and effect, including that all conditions
to the exercise of the Restructure Opportunity set forth in the First Amendment must be met by the deadline as extended by this letter in order for Accentia to avail itself of the Restructure Opportunity. 
  
 If the foregoing is agreeable, please execute this Restructure Opportunity
Extension Letter where indicated below and return it (and all counterparts) to the undersigned. The extension shall be effective upon receipt of duly executed counterpart originals of this letter from Accentia and each of the Guarantors. This is the
entire agreement between McKesson and the other undersigned parties regarding the matters set forth herein, superseding all prior discussions, drafts or negotiations. There are no third party beneficiaries of this Restructure Opportunity Extension
Letter. 
  

			
	 Best regards,
  
 MCKESSON CORPORATION

		
	 By:
	 	 /s/    Ana Schrank        

	 	 	Ana Schrank
	 Title:
	 	VP Financial Services

  
 [Signatures continued on next
page.] 
  

 3 

 MOAB Investments, LP 
  
 May 31, 2005 
  
 ACCEPTED, ACKNOWLEDGED AND AGREED 
 as of this      day of May, 2005. 
  

			
	
	 ACCENTIA BIOPHARMACEUTICALS, INC.

		
	 By:
	 	 /s/ Francis E. O’Donnell

	 Title:
	 	 Chairman & CEO

	
	 /S/ FRANCIS E.
O’DONNELL

	 FRANCIS E. O’DONNELL, JR., M.D.

  

			
	
	 REGENT COURT TECHNOLOGIES

		
	 By:
	 	 /s/ Francis E. O’Donnell

	 	 	 Francis E. O’Donnell, Jr., M.D.
 Managing Member

  

			
	
	 HOPKINS CAPITAL GROUP, LLC

		
	 By:
	 	 /S/ FRANCIS E. O’DONNELL

	 	 	 FRANCIS E. O’DONNELL, JR., M.D.

	 Title:
	 	 Managing Member

  

			
	
	 HOPKINS CAPITAL GROUP II, LLC

		
	 By:
	 	 /s/ Francis E. O’Donnell

	 	 	 Francis E. O’Donnell, Jr., M.D.
 Managing Member

  
 [Signatures continued
on next page.] 
  

 4 

 MOAB Investments, LP 
  
 May 31, 2005 
  

	
	
	/S/ DENNIS L. RYLL, M.D.        
	DENNIS L. RYLL, M.D.

					
	
	  
 MOAB INVESTMENTS, LP

		
	 By:
	 	 /S/ TIM D. RYLL

			
	 	 	By:	 	TIMOTHY D. RYLL
			
	 	 	 Title:
	 	 President, MOAB Management Co., Inc.

	 	 	 	 	Its General Partner of MOAB Investments, LP

  
  

 5 

 June 30, 2005 
  
 FIRST CLASS MAIL AND E-MAIL 
  
 Accentia Biopharmaceuticals, Inc. 
 324 South Hyde Park Ave., Suite 350

 Tampa, FL 33606 
  

	Attn:	 	Francis E. O’Donnell, Jr. M.D. 

  

	Re:	 	Second Modification of “First Amendment to Accentia Assumption of Debt and Security Agreement” dated as of February 9, 2005 (the “First Amendment”) Executed by
Accentia Biopharmaceuticals, Inc. (“Accentia”) and McKesson Corporation (“McKesson”). 

  

  
 Gentlemen: 
  
 You have requested that McKesson agree to a second extension of the deadline by which Accentia must act to satisfy the
conditions necessary to take advantage of the “Restructure Opportunity” described in Section 9 of the First Amendment. Pursuant to a letter agreement dated as of May 31, 2005 (the “First Restructure Opportunity Extension
Letter”), the previous deadline of May 31, 2005 was extended until June 30, 2005. Subject to the satisfaction of the conditions set forth below, McKesson agrees that the deadline by which the conditions set forth in Section 9 of the First
Amendment must be satisfied in order for Accentia to perform the Restructure Opportunity described therein shall be extended from June 30, 2005 until close of business California time on July 8, 2005. 
  
 It shall be a condition to the extension provided above that Accentia, and
each of the “Guarantors” (defined below) of the obligations owed to McKesson by Accentia, shall duly execute an original counterpart of this letter (the “Second Restructure Opportunity Extension Letter”) where indicated below and
deliver it to McKesson. The term “Guarantors” is defined in the First Restructure Opportunity Extension Letter, and includes Francis E. O’Donnell, Jr., M.D., Dennis L. Ryll, M.D., Regent Court Technologies, Hopkins Capital Group, LLC,
Hopkins Capital Group II, LLC, and MOAB Investments, LP. 
  
 Upon
so executing where indicated below, Accentia and each of the Guarantors, respectively, shall immediately and subject to no conditions precedent thereby acknowledge and agree as follows: 

 Accentia Biopharmaceuticals, Inc. 
 June 30, 2005 
  
 a. That as of the date hereof, that
certain “Accentia Assumption of Debt and Security Agreement” dated as of December 31, 2003 (as modified or amended in writing, from time to time, including by the First Amendment and the First Restructure Opportunity Extension Letter,
called the “Assumption Agreement”), remains in full force and effect in accordance with its express written terms, and each and any document or agreement executed by Accentia or any Guarantor in favor of or for the benefit of McKesson
remains in full force and effect (except as expressly modified or released in a writing signed by McKesson) subject to no defenses, counterclaims or offsets whatsoever, whether known or unknown, and whether legal or equitable in nature; 

 
 b. That each Guarantor hereby consents to the grant of the extension of
the deadline for Accentia to perform the “Restructure Opportunity” described in Section 9 of the First Amendment described above and agrees that such extension shall not give rise to any defense, counter claim or offset against any
obligation that any Guarantor owes to McKesson under any document executed by such Guarantor in favor of McKesson or under applicable law; 
  
 c. McKesson had no and has no obligation to provide the extension set forth in this Second Restructure Opportunity Extension Letter and in granting the
extension, McKesson is not establishing a pattern and practice or course of dealing of providing such extensions in the future, nor of modifying the Assumption Agreement in any manner whatsoever; and 
  
 d. Except as expressly modified in a writing signed by McKesson, the
Assumption Agreement remains in full force and effect, including that all conditions to the exercise of the Restructure Opportunity set forth in the First Amendment must be met by the deadline as extended by this letter in order for Accentia to
perform the Restructure Opportunity. 
  
 If the foregoing is
agreeable, please execute this Second Restructure Opportunity Extension Letter where indicated below and return it (and all counterparts) to the undersigned. The extension shall be effective upon receipt of duly executed counterpart originals of
this letter from Accentia and each of the Guarantors. This is the entire agreement between McKesson and the other undersigned parties regarding the matters set forth herein, superseding all prior discussions, drafts or negotiations. There are no
third party beneficiaries of this Second Restructure Opportunity Extension Letter. 
  

			
	 Best regards,
  
 MCKESSON CORPORATION

		
	 By:
	 	/s/ Ana Schrank            
	 	 	 Ana  Schrank

		
	 Title:
	 	 VP Financial Services

  
  
 [Signatures continued on next page.] 
  
  

 2 

 Accentia Biopharmaceuticals, Inc. 
 June 30, 2005 
  
 ACCEPTED, ACKNOWLEDGED AND AGREED 
 as of this              day of June, 2005. 
  

			
	
	 ACCENTIA BIOPHARMACEUTICALS, INC.

		
	By:	 	/s/ Francis E. O’Donnell, Jr. M.D.    
	Title:	 	Chief Executive Officer
	 	 	 
	 	 	 
	By:	 	/s/ Francis E. O’Donnell, Jr. M.D.    
	 	 	FRANCIS E. O’DONNELL, JR., M.D.
	 	 	 
	 	 	 
	REGENT COURT TECHNOLOGIES
		
	By:	 	/s/ Francis E. O’Donnell, Jr. M.D.    
	 	 	 Francis E. O’Donnell, Jr., M.D.
 Managing
Member

	 	 	 
	 	 	 
	
	HOPKINS CAPITAL GROUP, LLC
		
	By:	 	/s/ Francis E. O’Donnell, Jr. M.D.    
	 	 	Francis E. O’Donnell, Jr., M.D.
	Title:	 	Managing Member
	 	 	 
	 	 	 
	
	HOPKINS CAPITAL GROUP II, LLC
		
	By:	 	/s/ Francis E. O’Donnell, Jr. M.D.    
	 	 	Francis E. O’Donnell, Jr., M.D.
	Title:	 	Managing Member

  
 [Signatures continued
on next page.] 
  
  

 3 

 Accentia Biopharmaceuticals, Inc. 
 June 30, 2005 
  

			
	 /s/ Dennis L. Ryll,
M.D.            

	DENNIS L. RYLL, M.D.
	 	 	 
	 	 	 
	 	 	 
	 MOAB INVESTMENTS, LP
  

	By:	 	 /s/ Tim Ryll            

  
 By:

	 	 	 Title: President of MOAB Management Co., Inc.,
           Its General Partner

 _ 
  
  
  
  

 4 

 July 8, 2005 
  
 FIRST CLASS MAIL AND E-MAIL 
  
 Accentia Biopharmaceuticals, Inc. 
 324 South Hyde Park Ave., Suite 350

 Tampa, FL 33606 
 Attn: Francis E. O’Donnell, Jr. M.D.

  

	Re:	 	Third Modification of “First Amendment to Accentia Assumption of Debt and Security Agreement” dated as of February __, [sic] 2005 (the “First Amendment”)
Executed by Accentia Biopharmaceuticals, Inc. (“Accentia”) and McKesson Corporation (“McKesson”). 

  
 Gentlemen: 
  
 This is the “Third Modification of First Amendment” relating to the First Amendment referenced above. The two previous modifications related to
your request to extend the deadline by which Accentia was permitted to exercise the so-called “Restructure Opportunity” described in Section 9 of the First Amendment. Thus, although McKesson had no obligation to do so, McKesson extended
the deadline for Accentia to take advantage of and to perform the Restructure Opportunity first to June 30, 2005 in a letter agreement dated as of May 31, 2005 (the “First Restructure Opportunity Extension Letter”), and then to July 8,
2005 in a letter agreement dated as of June 28, 2005 (the “Second Restructure Opportunity Extension Letter”). The Restructure Opportunity has now expired without exercise thereof and there is no longer any right on the part of Accentia to
make use of that opportunity, nor does McKesson have any obligation to provide the opportunity described in Section 9 of the First Amendment to Accentia (or any other person or entity) nor to make any of the transfers described therein. 

 
 Due to the expiration of the Restructure Opportunity, you have requested
that McKesson extend the outside date by which Accentia must plus pay all “Obligations” owing to McKesson, including accrued and unpaid interest, all fees, costs and expenses incurred by McKesson in connection with the Obligations, plus
any other indebtedness owed by Accentia to McKesson (or to any affiliate of McKesson), other than in connection with the Biologics Distribution Agreement from June 30, 2005. Based on that request, although it has and had no obligation to do so,
McKesson is willing to grant the accommodations to Accentia described in Section A below, subject to the full and timely satisfaction of the conditions in Section B below. 

  

 
Acentia Biopharmaceuticals, Inc. 
 July 8, 2005 
  
 Capitalized terms not otherwise defined herein shall have the meaning they were assigned to
have in the Assumption Agreement, as amended from time to time including by this letter agreement (the “Third Modification of First Amendment”). 
  
 SECTION A. MODIFICATION OF FIRST AMENDMENT. Subject to the satisfaction of the conditions set forth in Section B below on or before July 11,
1005, McKesson agrees that the First Amendment shall be amended such that: 
  
 1. The definition of “Full Payment Deadline” shall be modified to read as follows: 
  
 “Full Payment Deadline” means the first to occur of (a)August 15, 2005, (b) four calendar days after the date Accentia or any of it
subsidiaries consummates an initial public offering of its stock, (c) the date any creditor of Accentia, Teamm, Analytica, BioVest, or of any of the Guarantors asserts a default and/or begins exercising any of its creditors’ rights and remedies
with respect to any of such persons or entities or their assets, and (d) the date any of Accentia, Teamm, Analytica, BioVest, or of any of the Guarantors becomes a debtor in a case under title 11 of the United States Code (the “Bankruptcy
Code”). 
  
 2. McKesson agrees that although it had a right
to charge interest at the Default Rate no later than June 30, 2005 due to the failure of Accentia to pay the sums due on that date, McKesson agrees to waive the right to charge the Default Rate which arose due to the failure of the Obligations to be
paid by June 30, 2005. However, McKesson retains the right to charge the Default Rate to Accentia (without notice in accordance with Section 5(a) of the First Amendment) for any new, additional or other Events of Default, including but not limited
to the failure of Accentia to pay all the Obligations by the Full Payment Deadline. 
  
 SECTION B. CONDITIONS. This Third Modification of First Amendment shall be immediately effective upon execution hereof by McKesson and Accentia, but shall cease to be effective if the following conditions are
not satisfied by close of business San Francisco time on July 11, 2005, in which case McKesson shall be free, without notice, to accelerate the Obligations and otherwise exercise its rights and remedies under the Assumption Agreement and applicable
law: 
  
 (1) McKesson shall have received payment in good,
collected funds of a fee (the “Modification Fee”) of $100,000, provided that fifty percent (50%) of the Modification Fee shall be applied to and reduce the Obligations owing to McKesson if and only if the Obligations are paid in
full on or before the earlier of the date that is (i) 21 calendar days of the date hereof, and (ii) the Final Payment Deadline; and 
  
 (2) Accentia and each of the “Guarantors” (as defined in the First Restructure Opportunity Extension Letter) shall have duly executed an
original counterpart of this Third Modification of First Amendment where indicated below and delivered it to McKesson. 
  
  

 2 

 Acentia Biopharmaceuticals, Inc. 
 July 8, 2005 
  
 SECTION C. ACKNOWLEDGEMENTS, WAIVERS,
ETC. Upon executing where indicated below, Accentia and each of the Guarantors, respectively, shall thereby immediately, and subject to no conditions precedent, thereby acknowledge and agree as follows: 
  
 1. That as of the date of execution hereof, that certain “Accentia
Assumption of Debt and Security Agreement” dated as of December 31, 2003 (as modified or amended in writing, from time to time, including by the First Amendment, the First Restructure Opportunity Extension Letter, the Second Restructure
Opportunity Extension Letter, and this Third Modification of First Amendment called the “Assumption Agreement”), remains in full force and effect in accordance with its express written terms, and each and any document or agreement executed
by Accentia or any Guarantor in favor of or for the benefit of McKesson remains in full force and effect (except as expressly modified or released in a writing signed by McKesson) subject to no defenses, counterclaims or offsets whatsoever, whether
known or unknown, and whether legal or equitable in nature; 
  
 2.
That each Guarantor hereby consents to the modifications of the First Amendment as described in this Third Modification of First Amendment and further agrees that such modifications shall not and do not give rise to any defense, counter claim or
offset against any obligation that any Guarantor owes to McKesson under any document executed by such Guarantor in favor of McKesson or under applicable law; 
  
 3. McKesson had no and has no obligation to provide the accommodations or the modifications set forth in this Third Modification of First Amendment and in
granting the accommodations and/or agreeing to the modifications set forth herein, McKesson is not establishing a pattern and practice or course of dealing of providing future accommodations, extensions or modifications, nor of modifying the
Assumption Agreement in any manner whatsoever; and 
  
 4. Except
as expressly modified in a writing signed by McKesson, the Assumption Agreement remains in full force and effect. 
  
 If the foregoing is agreeable, please execute this Third Modification of First Amendment where indicated below and return it (and all counterparts) to the
undersigned. The accommodations and other modifications shall be effective upon satisfaction of the conditions precedent set forth in Section B above. This is the entire agreement between McKesson and the other undersigned parties regarding the
matters set forth herein, superseding all prior discussions, drafts or negotiations. There are no third party beneficiaries of this Third Modification of First Amendment. 
  

			
	 Best regards,
  
 MCKESSON CORPORATION

		
	 By:
	 	 /s/ Ana Schrank

	 	 	 Ana Schrank
 Title: Vice President Financial
Services

  
  

 3 

 Accentia Biopharmaceuticals, Inc. 
 July 8, 2005 
  
 ACCEPTED, ACKNOWLEDGED AND AGREED 
 as of this 8th day of July, 2005. 
  

			
	
	 ACCENTIA BIOPHARMACEUTICALS, INC.

		
	By:	 	/s/ Alan M. Pearce    
	Title:	 	Chief Financial Officer
	 	 	 
	 	 	 
	/s/ Francis E. O’Donnell, Jr. M.D.     
	 FRANCIS E. O’DONNELL, JR., M.D.

	 	 	 
	 	 	 
	REGENT COURT TECHNOLOGIES
		
	By:	 	/s/ Francis E. O’Donnell, Jr. M.D.    
	 	 	 Francis E. O’Donnell, Jr., M.D.
 Managing
Member

	 	 	 
	 	 	 

  
 [Signatures continued
on next page.] 
  
  
  

 4 

 Acentia Biopharmaceuticals, Inc. 
 July 8, 2005 
  

			
	
	HOPKINS CAPITAL GROUP, LLC
		
	By:	 	/s/ Francis E. O’Donnell, Jr. M.D.    
	 	 	Francis E. O’Donnell, Jr., M.D.
	Title:	 	Managing Member
	 	 	 
	 	 	 
	
	HOPKINS CAPITAL GROUP II, LLC
		
	By:	 	/s/ Francis E. O’Donnell, Jr. M.D.    
	 	 	Francis E. O’Donnell, Jr., M.D.
	Title:	 	Managing Member

  

			
	
	 /s/ Dennis L. Ryll, M.D.

	DENNIS L. RYLL, M.D.

  

			
	
	MOAB INVESTMENTS, LP
		
	By:	 	/s/ Tim Ryll
		
	 	 	 By:    Tim Ryll

		
	 	 	 Title: President of MOAB Management Co., Inc.

	 	 	 Its General Partner

  

 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}]]